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PREFACE  
This thesis is divided into six chapters, including this one:  
Chapter 1:  
This is an introductory chapter that addresses the background, rationale and relevance of the study as 
well as the proposed aim and objectives. The general outline and structure of the thesis concludes this 
chapter.  
Chapter 2:  
This chapter provides a comprehensive literature review on discovery and patenting of Domperidone 
drug, and the urgent research, taking place toward the development of FDA approved oral 
DOMPpolymeric nanoparticle formulations. Included in this chapter is the historical background, 
mechanism of action (MOA) of domperidone, choice polymers, the use of computational chemistry and 
molecular modelling oral route of administration.  
Chapter 3:  
This chapter conceptualizes computer-aided drug design by discussing various molecular modeling and 
molecular dynamic tools and applications. The computational strategies needed to investigate 
comparative polymeric structural/conformational properties as well as methods used to analyze binding 
affinity are explicated upon.  
Chapter 4: (Published work- this chapter is presented in the required format of the 
journal and is the final version of the accepted manuscript)  
This chapter employs molecular modelling studies to provide underpinning insight at the molecular 
level of the DOMP-polymer nanocrystal interactions to substantiate the experimental   studies. This 
included an understanding of the impact of polymers on the size of nanocrystals and their associated 
stability characteristics.  
Chapter 5: (Published work- this chapter is presented in the required format of the 
journal and is the final version of the accepted manuscript)  
This chapter identifies shortcomings that linked with PD pharmacological treatment and substantiates 
the emergence of the role played by In Silico investigation in formulating and validating new 
compounds and the use of nanopolymers to achieve more effective therapy.  
Chapter 6:   
  
   III This is the final chapter that proposes 
future work and concluding remarks.  
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ABSTRACT  
  
Parkinson’s disease is symbolized by resting tremor, rigidity, and bradykinesia caused by the loss of 
dopaminergic neurons in the substantia nigra, the presence of Lewy bodies, and a decent response to 
levodopa. However, a domperidone (DOMP) supplement is often necessary to remedy the nausea and 
vomiting caused by this prodrug and its therapeutic counterparts, namely metoclopramide must be 
supplemented with domperidone therapy to treat nausea and vomiting. Even though it is potentially the 
best antiemetic by reason of its unique mechanism of action, this drug presents with low solubility. In 
addition to a plethora of adverse effects; these shortcomings necessitate the use of polymeric 
nanoparticles (nano-polymers) to boost the dissolution rates by improving the solubility of DOMP. The 
resultant enhancement in bioavailability of the active ingredient is envisaged to address the challenge 
of increase adherence and reduce frequency dosing through controlled release.  Therefore, the aim of 
this study was to employ molecular modelling approaches to rationalize the selection of suitable 
polymers for use in the production of stable domperidone nanopolymers with enhanced bioavailability. 
Polymers-combinations were designed and synthesized by collaborators and structures were made 
available for this study. Docking and binding free energy calculations were carried out for on 12 
polymers-DOMP complexes. Results showed stability for all complexes, converging at 20ns over a 
50ns simulation. Of the polymer-complexes, the HPMC-PVA-DOMP (25.22 kcal/mol) system showed 
the most optimal binding free energy based on the intermolecular interactions. This demonstrates 
favorable affinity of DOMP to the polymer, thus justifying its use in Parkin’s diease therapy. The 
Molecular modelling tools provided in this study underpin knowledge at a molecular level of DOMP-
polymer nanocrystal interactions. This was further substantiated by collaborative experimental studies. 
This study has contributing immensly to the understanding of nano-polymers toward enhanced therapy 
against Parkinson’s disease.    
  
Isiqephu  
Isifo i- Parkinson sibonakala ngokuqhahazela, ukuqina komzimba ngokungajwayelekile kanye ne 
bradykinesia okudalwa ukungasebenzi ngendlela kwama-dopaminergic neurons kwi-substantia nigra, 
ukuba khona kwama-Lewy bodies kanye nokusebenza ngendlela kwe-levodopa. Kodwa idomperidone 
(DOMP) eyisilekeleli iyadingeka ukwelapha inhliziyo encane kanye nokuphalaza okudalwa i-prodrug 
kanye nendlela elilapha ngayo, esibala i-metoclopramide kumele ilekelelwe ngedomperidone therapy 
ukuze ilaphe inhliziyo encane kanye nokuphalaza. Noma le-prodrug ibe iintiemetic engungqa phambili 
kodwa ngenxa yesizathu sendlela esebenza ngalo incibilika ngokungagculisi. Ngaphezu kwalokho 
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esikubala kwizingqinamba ze-plethora kuba nesidingo sokusetshenziswa kwama- polymeric 
nanoparticles (nano-polymers) ukukhuphula izinga lokuncibilika ngokudlondlobalisa i-solubility ye-
DOMP. Lo mthelela ukhulisa i-bioavailability yesithako esisebenzayo ibukwa njengendlela 
yokumelana nengqinamba yokunyusa ukunamathela futhi iphinde inciphise izinga lokudedela i-dosing. 
Ngakho-ke lolucwaningo luqonde ekusebenziseni izindlela ze-molecular modelling ukuqonda indlela 
yokukhetha ama-polymers afanele ekusetshenzisweni ekwakhiweni kwe-domperidone nanopolymers 
azoba-stable futhi ane-bioavailability ethe xaxa. Izingxubevange zama-polymers akhiwe futhi enziwa 
ama-collaborators nezakhiwo ebezikhona kulolu cwaningo. Izibalo ze-docking kanye ne-binding free 
energy zenziwe kuma polymers-DOMP complexes ayishumi nambili. Imiphumela ikhombise istability 
kuwona wonke ama-complexes, abehlangana ku 20ns esikhathini esibalelwa kwizilinganiso eziwu 50 
ns. Kulama polymer-complexes, i-HPMC-PVA-DOMP (-25.22 kcal/mol) iwuhlelo olukhombise i-
binding free energy enkulu ehlaluka kuma-intermolecular interactions. Lokhu kukhombisa 
ukunamathela okuhle kwe-DOMP kwi-polymer, okuyimbangela yokusetshenziswa ekulashweni 
kwesifo se-Parkin. Amathuluzi e-molecular modelling kulolu cwaningo asinike ulwazi ezingeni lama-
molecules lokusebenzisana kuma DOMP-polymer nanocrystals. Lokhu kuphinde kwagcizelelwa 
ngokuhlolwa okunobambiswano. Lolu cwaningo selusize kakhulu ekuqondeni kahle hle kwama nano-
polymers ekukhulisweni kolapho oluqondene nesifo se-Parkinson.       
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CHAPTER 1  
1. Introduction   
1.1. Background and Rationale of the study  
Neurodegenerative diseases (ND) transpire when neurons in the brain and spinal cord and 
begin to deteriorate (Maiti et al., 2017). As neurons continue to deteriorate symptoms 
progressively worsen and in certain cases patients lose ability move normally, think clearly, or 
generally function on a daily basis (French & Muthusamy 2016). Finally, the majority of these 
diseases are injurious.   
Parkinson's disease (PD) is an extremely incapacitating neurodegenerative disorder that 
develop in motor circuit disturbance and eventually, causes deterioration of movement (Beall 
et al., 2013; Mariani et al., 2005). This condition is due to the selective degradation of the 
dopaminergic neurons in the substantia nigra pars compacta in the midbrain, which 
consequently results in the pathological symptoms namely bradykinesia, resting tremor, 
postural instability and rigidity (Bhatia 2012). It was originally suggested that patients who 
develop PD were exposed to an environmental trigger(s) e.g. pesticides that caused the onset 
of the disease, but more recently, a significant genetic component, paired with environmental 
factors have been incriminated in disease pathogenesis (Hatcher et al., 2008; Freire & Koifman 
2012). Currently, there are eight genes (Parkin, PINK1, LRRK2, SNCA, DJ-1, ATP13A2, 
EIF4G1 and VPS35) that have been candidly associated with PD (Klein & Westenberger 
2012).    
A wide range of treatment has been availed to reduce symptoms related with Parkinson’s 
disease since it cannot be cured using pharmacological treatment. The disease continues to 
progress and no medication has been discovered to slow down or stop PD disease progression 
in patients (Oertel 2017).  
Even though a lot of ground has been covered since the introduction of Levodopa made 
resulted in breakthrough in the treatment of motor symptoms, there still remains more 
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therapeutic avenues to be explored in the arena of Parkinson’s symptoms (Brück 2002). This 
void in symptomatic relief regimens for PD has a sparked greater interest in research to come 
up with better drug delivery strategies and drug re-inventions to bridge the gap of therapeutic 
inadequacy and multiple side effects caused by the current treatment regimens to be filled since 
symptoms differ from person to person (Rodriguez-Aller et al., 2015).   
Nano-drug delivery are now the critical approach to scale up PD treatment solubility, drug 
discharge profiles, and to lower dosing recurrence and side effects (Parhi et al., 2012). The 
utilization of Nano-drug delivery transport has proved a critical method of to revamp managing 
patients with neurodegenerative diseases. Nanoparticles-based drug transport mechanisms 
have given rise to controlled and efficacious release of drugs at the affected neurons, improved 
solubility, bioavailability and strength (Ravichandran 2009).         
Computational methods are becoming indispensable in drug delivery and development 
ventures, they are rapidly intensifying in terms of growth, application and popularity (Hopkins 
2008). Molecular docking and molecular dynamics in particular are regarded very essential in 
interpretation of the binding systems, conformational investigation and computing the binding 
affinities between drugs and sundry systems as protein, polymers and other bioorganic 
molecules (Okimoto et al., 2009). Sundry molecular modelling apparatus have been hugely 
harnessed in to grasp the progression of drug delivery systems and pharmaceutics in general 
(Ullah et al., 2018).  
  
1.2 Aims and objectives  
1. The aims of this study were therefore: (1) to provide insights of the structural and 
conformational features in the designed polymeric nanoparticles. In order to achieve aim 
1 the objectives of this study were therefore:   
1.1 To explore the structural and conformational dynamics of the designed 
nanopolymers via molecular dynamics simulations   
1.2 To explore the binding mechanism of the designed polymers and their interactions 
modes with DOMP and   
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1.3 To provide a technical guidance on how to set up a simulation protocol for 
investigating drug interactions with polymeric targets.  
  
2. To provide comprehensive molecular insight into the interaction and the       
conformational landscape of a series of polymeric nanoparticles structures, In order to 
achieve aim 2, the objectives of this study were therefore:   
2.1 To understand the structural and conformational landscape as well as the binding 
mechanisms of DOMP-nanopolymer by applying a wide range of molecular 
modelling tools, such as molecular docking, molecular dynamics and 
conformational analysis protocols.  
  
3. To apply experimental and molecular modelling tool to design the first account of stable 
DOMP-nanopolymeric particles with enhanced dissolution rate for increased 
bioavailability:  
  
In order to achieve aim 3, the objectives of this study were therefore:  
3.1 To design and prepared different DOMP nanopolymeric particles with HPMC, 
PVP, PVA, ethyl cellulose (EC) Eudragit and Pluronics,   
3.2 Characterize the DOMP nano-polymeric particles in terms of particle size, zeta 
potential, surface morphology, in vitro drug release,    
  
4 To employ in silico molecular modelling strategies such as molecular docking and dynamics in 
order to provide in-depth knowledge into the molecular nature of the designed nanoparticles, 
binding mechanism and polymer choice in relation to the overall physicochemical properties 
and anti-Parkinson’s activities of the processed Domperidone particles. (Ullah et al., 2018)  
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1.3 Novelty and Significance of study       
                                                                                                         
 The average global life expectancy of many populations throughout the world now extends late 
into the eighth decade, and the prevalence of most neurodegenerative disorders increases 
dramatically with advancing age (Abegunde et al., 2007). Parkinson’s disease is a gradual 
deterioration of the central nervous system that essentially affects the aged. An Investigation on 
588 newly diagnosed patients showed there are over 91% more men who are plagued by PD than 
there is among women and only 4% of the patients were less than 50 years of age yet the frequency 
increased for the more aged, above 60 years.  PD incidences are expressed at all ages, nonetheless 
are still rare in people youthful patients, under 40 and usually induced by an inherited or 
impromptu genetic effects deformities (Fahn & Sulzer 2004).Thus, if efficient remedies or 
preventive interventions for Parkinson’s disease and other neurodegenerative disorders are not 
discovered in the near future, the financial, societal and emotional costs of these aging-related 
brain disorders will be overwhelming (Maresova et al., 2016).  
  
 Figure 1.1: Pie chart showing the foreseen increase in global prevalence of PD   
Notable progress has already been made finding the treatment for nano-polymeric delivery of 
DOMP. Despite these attainments using polymers in transdermal administration these and other 
nanopolymers still need to explored for oral delivery (Shah et al., 2011). It cannot vaguely be 
assumed that the same polymers are able to deliver this 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒2  Receptor antagonist 
transdermally, will also deliver against the peculiar odds of first-pass effect in the oral route of 
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transport (Kaestli et al., 2008). Therefore, it is of necessity for polymers that not only have 
favorable properties for boosting the dissolution of DOMP, but also possesses protective qualities 
to traverse the drug across the gastrointestinal-tract without exposing it to metabolism and finally 
reducing the frequency of repeated daily dosing through controlled release.   
Various means of exploring the interactions between the polymer and DOMP became needful. The 
investigations were to be done using computational simulation of structure and binding selected 
polymers with the antiemetic as a way of buttressing the experimental trials on the dissolution of 
the drug with different combinations of polymeric nanoparticles (Rodriguez-Aller et al., 2015). 
There is therefore a need for growing advancement in drug design. This has provoked us to 
scrutinize potential polymers, based on the interactive features of DOMP, and suggest potential 
efficient formulations stemming from pronged research. Beyond the desired oral DOMP 
polymeric nanoparticle (DOMP-nanoparticle) formulation, this research will indeed usher several 
step closer finding a sure pattern for boosting low solubility drugs the class of BSC II and BSC IV 
for exceptional drug delivery (Rodriguez-Aller et al., 2015; Ullah et al., 2018).   These findings 
therefore showcase the potential of these systems in enhancing patient therapy and treatment of 
ND, thereby ultimately improving the quality of life and saving lives.  
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CHAPTER 2  
2. Background on Domperidone  
2.1 Introduction   
Parkinson’s disease, also known as originally known as “shaking palsy” is   the second most common 
degenerative disorder, which embodies a growing burden known to have affected more than 7 million 
people worldwide with an average age of 60 years, showing it to be prevalent among the aged(Lewis 2012; 
Zampieri et al. 2010). Parkinson’s disease is a movement disorder with dopamine producing neurons and 
substantia nigra undergoing degeneration. And its progressive adult onset disease and it gets more common 
with age affecting about 1% of people over 60years(Tysnes & Storstein 2017).   
Most of the time there is no known cause but in a few cases there might be a genetic cause like mutation 
and currently there are eight genes (PINK 1, PARKIN, LRRK2, SNCA, DJ-1, ATP13A2, EIF4G1 and 
VPS35)(Kong et al. 2014; Erer et al. 2016). It is widely accepted that genetic factors combined with 
environmental risk factors make for the risk factors. Figure 2.1 portrays effects various risk factors that are 
associated with PD.   
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Figure 2.1: A diagram of Risk factors that are associated with Parkinson’s disease. The diagram shows 
multiple factors that exhacerbate oxidative stress and thus resulting in Dopaminergic Cell 
Neurodegeneration. 
  
Presently, the pharmacological and non-pharmacological (surgical and electrodes e.t.c.) regiments endorsed 
for PD offer only symptomatic relief for patients. As these regiments are not able to halt or reverse the 
neurodegenerative process, PD remains incurable. The motor symptoms can be reduced by many drugs that 
increase the DA level in the central nervous system (CNS) or mimic its effects. The gold standard for the 
treatment of PD nowadays is Levodopa, a DA precursor (Politis & Lindvall 2012). The prodrug that 
adequately addresses motor symptoms. Figure 2.2 shows some of the key medicines that are used 
individually or as adjuncts in treating PD symptoms.   
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Figure 2.2:  The key drugs in the Parkinson’s symptoms .  
Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in 
the brain (Fernandez 2012). Levodopa changes into dopamine in the brain, helping to control movement. 
Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. 
Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting (Olanow et al., 
2014)(Figure 2.3).  
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Figure 2.3: Complete diagram of the distribution and metabolism of Levodopa and 
Levodopa/Carbidopa.Levodopa alone yields less dopamine than Levodopa administered with carbidopa 
into the brain thus Levodopa with Carbidopa is more efficacious.   
 
Literature throughout the medical field confirms PD is caused by the deficiency of naturally occurring 
dopamine in the brain, which regulate movement. Carbidopa counteracts the catabolism of levodopa’s side 
effects (Zibetti et al., 2014). Unfortunately these peripheral inhibitors do not sufficiently curb side effects 
caused by Levodopa, metoclopramide and other centrally acting dopamine.   
  
2.2 Discovery and structure of Domperidone  
From the time of its synthesis in 1974 by Janssen pharmaceutica Domperidone has been employed as an 
antiemetic, gastroprokinetic agent and galactagogue (Smolina et al., 2016). Figure 2.4 projects the structure 
of this unique dopamine antagonist. It was confirmed that domperidone is in circulation in 58 countries, 
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encompassing Canada, and there is a global ordeal in using this agent, both as a remedy for gastroparesis as 
well as a general antiemetic.  A cogent antidote to nausea and vomiting associated with the peripheral 
formation of dopamine due to Parkinson's treatment, namely levodopa and bromocriptine. Although both 
metoclopramide and domperidone have similar anti-emetic properties, domperidone has a greater advantage 
than metoclopramide in that it does not cross the blood-brain barrier, therefore it has reduced central nervous 
system effects like drowsiness and therefore preferred to metoclopramide. The clinical use of 
metoclopramide, particularly for chronic treatment, is additionally dwindled by its capability of unfavorable 
effects like drowsiness, akithesia, restlessness syndrome, insomnia, lassitude, and fatigue. The unique 
structure of  has a bearing on its more tolerable effects that are yet to be computationally investigated using 
quantitative structure-activity relationship.  
  
Figure 2.4: The 2D structure of Domperidone  
  
2.3 Domperidone’s Unique Mechanism Of Action  
Domperidone is a unique peripheral 𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒2 -receptor (D  ) antagonist which is related to haloperidol 
and other butyphenone tranquilizers, but different to the benzamides such as metoclopramide and cisapride. 
Its manner of action and chemistry separate it from other gastrokinetic drugs. As such it is an adherent to 
D2 subtype receptors in the brain and stomach. Regardless of its nominal level of CNS action, domperidone 
is a potent antiemetic. Such potency is indicative of its action at the (CTZ), which is situated in the fourth 
ventricle of the brain yet external to the blood-brain barrier (Reddymasu et al., 2007a) (Figure 2.5).  
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Figure 2.5: Mechanisms of action of domperidone (Reddymasu et al., 2007b)    
  
2.4 Domperidone is a drug with multiple uses in the field of medicine:   
Many of the mainstream PD drugs, namely Levodopa, bromocriptine, Ropinirole, Pramipexole, 
Carbergoline and other centrally acting drugs .Therefore , Domperidone has many uses within the 
pharmaceutical arena. Over the past decades it has been employed as an antiemetic and prokinetic. Its use 
as a galactagogue is still under investigation in many countries where it has been accepted. Figure 2.6 
demonstrates the many medical conditions in which DOMP is utilized.   
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Figure 2.6 : Known mainstream uses of Domperidone (Prepared by author).  
  
2.5 Physicochemical properties of DOMP and its effects on various routes of administration  
  
Domperidone has been availed all over the world in sundry dosage forms namely oral tablet, oral solution 
and rectal suppository (Palem et al., 2013). It wields a molecular weight of 425.9. Time taken to reach 
plasma peak levels ranges from 10 to 30min reliant on whether it is given by intramuscular (IM) or oral 
administration (30min). Even though the bioavailability of IM administration is high the anti-emetic has 
been proven to present intense adverse effects such as dystonia, galactorrhoea, and gynaecomastia at high 
concentrations especially with parenteral administrations (Brück 2002). When given by injection has also 
been associated with convulsions, arrhythmias, and cardiac arrest (Rocha & Barbosa 2005). Such fatalities 
have restricted these routes of administration. On the other hand, the oral route of administration has a 
trifling bioavailability of 13-17%, and limited plasma half-life 7-9 hrs. This is likely to be caused by 
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inadequate assimilation coupled with a first pass effect with oral dispensation. For the relief of nausea and 
vomiting in PD patients, domperidone is taken for up to 12 weeks, which necessitates sustained regimen 
(Shazly et al., 2018; Palem et al., 2013).   
  
2.6 Transition of DOMP-nanopolymers from transdermal to oral route of administration    
On the basis of the promising outcomes transdermal patches of nausea and vomiting, the domperidone oral 
administration can be adopted as a controlled drug delivery system for medication of the same symptoms 
in PD (Ahmed et al., 2018). The investigation of the transdermal polymeric delivery using patches has 
already shown through in vitro cellophane and in vivo rabbit formulations that a release of more than 32.50% 
can easily be attained within a 24 h period.  Even though work has already been made towards the 
advancement of domperidone transdermal patches, there is a great demand to transition to oral delivery 
intense pharmacokinetic and pharmacodynamics research would be necessary to launch the usefulness of 
oral delivery (Shah et al., 2011). Fig 2.9 below gives a snippet of advantages and disadvantages, thus 
validating emergent move reconsider adoption of oral administration for DOMP nanopolymers.   
Figure 2.7: Summary of considerations to be made upon transition to oral administration of drugs (Prepared by 
Author).    
 
  
  
  15  
  
  
2.7 Adverse effects and low solubility of Domperidone   
Domperidone is deemed a choice prospect since it is the most tolerable drug among the antiemetics largely 
due to its action being restricted to the peripheral nervous system, while metoclopramide has a great deal of 
blockade interaction with !! –Receptors (Prajapati & Patel 2010; Paradkar et al. 2016). Even though its 
effects do not result from the central nervous system CNS they still pose significant concern since they 
affect patient adherence and have been suspected to have deleterious effects on the cardiac system among 
other adverse effects(van Noord et al. 2010; Hashmi & Al-Salam 2015; Boyce et al. 2012). Figure 2.8 
highlights some of the adverse effects that are associated with Domperidone.  
  
  
Figure 2.8: Adverse effects of Domperidone (Prepared by Author).  
  
 
16  
  
2.8 The emergence of polymers salvaging the drug crisis in Parkinson’s disease   
Both in the near- and medium-duration, we can anticipate the boom of a plethora of drug Nano-polymeric 
delivery transport utilization(Ullah et al. 2018). Even as both organic and inorganic science is work in 
progress, controlled-release polymer tools and liposomes will possibly persist to have the most immense 
clinical influence for the near future. It is broadly believed that with continued resources, medicine and the 
area of drug transport will be a significant recipient of nanotechnology for years to come(RodriguezAller et 
al. 2015).  
  
Deficient aqueous solubility is the critical limiting area of plenty of drug candidates in their developing 
initiative in the world market regardless of having promising pharmacokinetic action. The low water 
solubility of drug issues into low dissolution rate with consecutive limited and irregular absorption and 
eventually bounds the clinical efficiency(Rodriguez-Aller et al. 2015). The advancement of polymers is the 
new arsenal to the pathways of pharmaceutical companies. Employing nanotechnology makes it attainable 
to boost the transport of insufficiently water-soluble medicine; intended relay of drugs in a cell- or tissue-
precise approach; transcytosis of drugs beyond tight epithelium and endothelial membranes(Alam et al. 
2010); transport large macromolecule drugs to intracellular areas of operation; multi-transport of drugs or 
curative approach for joint therapy; determination of locations of drug transport by joining curative agents 
with the  imaging approaches; and real-time read on the in vivo efficiency of a therapeutic agent. The above 
are some of the many compelling rationales that nanotechnology carries immense possibilities for drug 
transport (Farokhzad & Langer n.d.).   
There are sundry characteristics that are essential for profitable enhancement and production of targeted 
drug transport carriers that are employed in the treatment of neurodegenerative disease among others (Gu 
et al. 2008; Decuzzi et al. 2009). Figure 2.9 demonstrates three of the most essential qualities of any given 
polymeric nanoparticle for use in pharmaceutical formulations.  
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Figure 2.9: Essential qualities of polymeric nanoparticle in formulations (Prepared by Author)  
  
The advancement of polymeric nanoparticles (NPs) for targeted transport and controlled drug discharge 
likely boosts the therapeutic index (beneficial range) of medicines(Masood 2016). Such an enhancement is 
particularly important when dispensing low solubility drugs that have toxicities that usually reduce their 
dose, resulting in suboptimal efficiency(Rodriguez-Aller et al. 2015).  
2.9 The inevitable merge of Nano polymers with computational chemistry  
Nano-drug transport methods are performing a vital task in conquering these obstacles and ushers to fresh 
avenues for effective therapy in neurodegenerative disease. Domperidone, a poorly water-soluble d receptor 
antagonist, has long been reported to have antiemetic properties a broad spectrum of nanoparticles has been 
refined and used efficiently (Venkatesh et al., 2006). Diversified forms of lipophilic and hydrophilic 
parkinsonian drugs can be conjugated with assorted nanoparticles. The unification of molecular modeling 
with experimental verdict has been largely embraced in biomedical research, containing material science 
(Silindir Gunay et al., 2016). The molecular modeling implements are capable of providing more 
morphological acumen into polymer-target interactions when experimental methods fail to operate large 
molecular complexes (Ullah et al., 2018).   
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Table 2.1: Showing choice polymers and their properties 
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The use of polymeric nanocrystals in molecular modelling is young and developing branch, however it is 
not an entirely new. There is enough work that has been done to confirm the enormous potential this arena 
has in combination with molecular modelling and computational chemistry (Ullah et al., 2018). In combined 
experimental and computational chemistry study, all of the above mentioned polymeric nanoparticles 
(PVA,PVP,HPMC, EUD, Pluronic and Ethocel researchers proved to have a lofty dissolution rate and 
significant boost therapeutic on the potential was achievable even with a drug of  low solubility (BSC 
II)(Gulzar et al. 2015; Ndlovu et al., 2019). This research will provide molecular insight into methods of 
binding of optimal polymers to the surfaces of domperidone.  
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 CHAPTER 3 
 
3.1 Introduction 
Computational chemistry is a field in chemistry which deals with the use of mathematical theories using computer 
simulation of chemicals and biochemical systems with the intent of acquiring solutions to medical challenges. 
This allows scientists to study chemical reactions virtually through the use of computers as opposed to empirical 
chemical reactions in a laboratory. Computational chemistry encompasses a variety of methods and theories, 
which contribute to solving problems in chemistry. This means atomic interactions can be portrayed in two ways: 
quantum mechanics (QM) and molecular mechanics (MM)(Jensen n.d.; Gil et al., 2011). Quantum mechanics 
solely focuses on electrons, and electron distribution is used to model the interaction between atoms. Whereas 
Molecular Mechanics uses atoms and focuses on classical Newtonian mechanics; modeling atomic interactions 
as a function of bond angles and bond length, non-bonded forces, and dihedral angles. This chapter gives an 
introduction to the computational and theoretical tools applied in this study. Theories used in MM and molecular 
dynamics (MD) applicable to the current study namely Schrödinger equation, the Born-Oppenheimer 
approximation and potential surface energy (PES). 
3.2 Quantum Mechanics 
Quantum Mechanics is a theory that describes the wave-like motion of sub-atoms particles, having 
discovered that electrons did not follow the Newtonian motion. Quantum Mechanics (QM) is one 
of the most well-decorated aspects of physics. The fundamentals of QM were laid down on Matrix 
Mechanics in the 20th century by a group of German scientists and later, in 1926 Erwin Schrödinger 
advanced wave mechanics, which is presently a key player in explaining quantum phenomena. The 
quantum theory interprets the behavioural characteristics of sub-atomic particles, namely electrons at a 
nanoscopic level. (Shrodinger1926). The electrons of an atom are considered as small sachets of energy i.e. 
quantum particles. Different energy states are correlated with peculiar quantum numbers. The allocation of 
quantum numbers is guided by particle properties such as; the spin of particle and electronic state of each 
molecule. Whether by release or addition, the shift in energy ensues in the form of a photon which is computed 
into a wave. The investigation of a biomolecule by QM involves the layout of nuclei with analogous electrons, 
in a three-dimensional zone. The electrons are profiled using the continuous electron density method, and the 
energetics quantified were expounded by the Schrödinger equation whereas Born-Oppenheimer approximation 
coupled with the Hartree-Fock self-consistent field which maps density of the system. 
  
 
3.2.1 The Schrödinger equation 
Regular Newtonian physics is insufficient in explaining or describing the behavior of small particles such 
as nuclei and electrons. Schrodinger’s equation is elementary to modern physics; it describes the conduct 
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of electrons in a molecule as wave-like action and how the molecular system transcends time (wave 
mechanics). QM explains Schrödinger’s equation and displays the interaction in terms of a wave-like 
function, which is a mathematical function that is used to estimate the electron distribution. Using electron 
distribution other characteristics of a molecule can be concluded, e.g. the part of the molecule that isprone to 
nucleophilic or electrophilic attack. In the realm of computational chemistry, the time-dependent equation is the 
most widely used among Schrödinger’s equations, which is dependent on time and average of a system (time-
dependent wave operation, Ψ). The plainest expression of the Schrödinger equation is given as a sum of its 
operators: 
HΨ = EΨ                                                      (3.1) 
H = T + V                                                    (3.2) 
Where H is the Hamiltonian operator (total energy of a system), T is the kinetic energy operator of the 
system and V is the potential energy operator. The Hamiltonian operator can also be detailed as: 
H = [-
ℎ2
8𝜋2 
 ∑ 𝑖
1
𝑚𝑗
 (
𝜕2
𝜕𝑥2
 + 
𝜕2
𝜕𝑦2
  +   
𝜕2
𝜕𝑧2
)] + ∑ 𝑖
𝑒𝑖𝑒𝑗
𝑟𝑖𝑗
                                            (3.3)             
 
The Schrödinger equation is highly complicated, and it constitutes a multitude of mathematical equations and 
cannot be solved for a molecular system, nevertheless, an answer can be given by a compensatory Born-
Oppenheimer approximation. 
 
 
 
3.2.2 Born-Oppenheimer Approximation Theory 
 
Max Born and J Robert Oppenheimer, who were physicists in their own right, submitted the Born- 
Oppenheimer approximation, which solves the perceived problem of segregation of nuclei wave function 
to that of the electrons. Electrons are considered to be lighter weight to that of nuclei, thus possessing 
increasing velocity and move rapidly to nuclei motion (Pisana et al. 2007). Therefore, the location of electrons 
molecules is determined by the location of the nuclei. This gives room for the Schrödinger equation to be 
solved for the kinetic energy of the electrons alone since the kinetic energy for the nuclei will remain 
steady.(Woolley,1991;Gu et al, 2008;Wudka,1990; Bludman, 1954). The disparity in velocities of nuclei and 
electrons permits the use of the Born-Oppenheimer approximation, reducing the complexity of the wave 
function of the Hamiltonian equation. 
 
The simplified wave function: 
                        Ψ (𝑟𝑒𝑙𝑒𝑐) = Ψ (𝑟𝑒𝑙𝑒𝑐) (Ψ (𝑟𝑛𝑢𝑐𝑙)                                                                  (3.4) 
 
 
Equation (4) is converted: 
                         𝐻𝐸𝑁Ψ (𝑟𝑒𝑙𝑒𝑐) = 𝐸𝐸𝑁Ψ (𝑟𝑒𝑙𝑒𝑐)                                                                   (3.5) 
Whereby 𝐻𝐸𝑁 articulates a contrast between terms based interaction with fixed nuclear positions ( 𝑉𝑁𝑁 ) 
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or their interaction with the non-fixed electron positions. Eq. (3.6) shows 𝐸𝐸𝑁, which is derived from 2 
sources being the oscillating electron co-ordinates and fixed nuclear coordinates. 
                        (𝐻𝑒𝑙 + 𝑉𝑁𝑁 ) Ψ (𝑟𝑒𝑙 ) = 𝐸𝐸𝑁 Ψ ( 𝑟𝑒𝑙 )                                                      (3.6) 
The most plausible explanation of the electron motion within a molecule is given by the electronic 
Schrödinger equation, which is most accurate when applied to the ground electronic states. Evaluation of 
equilibrated states and construction of the potential energy surface curve may only be done when the 
equation has been resolved (Deslauriers & Wieman 2011). 
 
3.2.3 Potential Energy Surface 
 
The potential energy surface is a mathematical connection, often presented graphically, between the 
energy of a molecule with its geometry by working out solutions to the time-dependent Schrödinger 
equation. This theory birthed the Born-Oppenheimer approximation described above, where electrons 
differ in accordance with the positional state of the nuclei such a way that the potential energy surface is 
taken as the potential of atoms to collide with each other in a molecule (Peter W. Atkins n.d.)’(Woolley 
1991). A potential energy surface exhibits high potential energy domain, implying high-energy nuclear or 
molecular conformations and low energy domains implying low energy conformations. The potential 
energy surface is employed in computational chemistry to investigate the lowest energy state and the 
positional geometry of a molecule at this state (Peter W. Atkins n.d ; Elsawy et al., 2005). 
The potential energy function is therefore described as follows: 
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Figure 3.1: Graphical representation of a 2-D potential energy surface (PES). 
 
3.3 Molecular docking 
Molecular docking is conventionally used in structure-based drug design to determine the accurate 
configuration of ligand to the polymer targets and to surmise the stability of polymer-ligand interaction. 
Molecules such as inhibitors or other drug competitors are analyzed in the active sites of macromolecules. 
A macromolecule is described as a very large molecule as a colloidal particle, protein or especially a 
polymer composed of hundreds or thousands of atoms. The ligand-receptor binding is calculated as 
follows: 
𝐸𝑏𝑖𝑛𝑑𝑖𝑛𝑔  = 𝐸𝑡𝑎𝑟𝑔𝑒𝑡 + 𝐸 𝑙𝑖𝑔𝑎𝑛𝑑 +  𝐸𝑡𝑎𝑟𝑔𝑒𝑡−𝑙𝑖𝑔𝑎𝑛𝑑                                             (3.7) 
 
There are ample molecular docking tools that are employed for academic and commercial purposes. 
There are two primary steps in docking: 
1. Sampling configurations of a ligand in the binding site of the receptor molecule. Numerous   conformations 
of the docked complex can be sampled using different algorithms to attain results. 
The "lock and key" model describes the ligand-receptor as rigid structures, or the ligand may 
show flexibility by irregular or simulation-based methods. The latter algorithm is the most 
commonly used approach since it permits a more rational fit of the ligand to the polymer (Zhang et al. , 2008). 
2.  Using scoring functions to rank different conformations. The scoring function may be based on 
contracts that are more statistically favored, MM force fields or pre-existing protein-ligand 
binding affinities (Geng et al., 2013). 
 
Molecular docking is associated with many discrepancies; as such docked compounds are often 
criticized due to incorrect binding sites or choice of the docked complex. Due to these matters, all 
docked complexes in this study were substantiated with MD simulations and the stability of the 
ligand at the binding site was displayed. 
 
3.4 Molecular Mechanics 
Molecular mechanics (MM) is an experimental approach whose fundamentals are revealed from the 
classical laws of physics in the forecasting of chemical characteristics of molecules. MM is usually 
employed in enormous molecular systems to estimate molecular structures and corresponding potential 
energies of molecular arrangements.(Case et al., 2005; Peter W. Atkins n.d.; Schrodinger, 1926). The 
electrons in the particular systems are absolutely ignored; however, each atom rather, specifically the 
atomic nuclei and related electrons are considered as a single particle. Definitive removal of electrons in 
the system is validated on the grounds of the Born –Oppenheimer approximation, which claims that the 
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electronic and nuclear motions can be disjointed from one another and accounted for individually. Energy 
differences between conformations are more consequential in such calculations than absolute potential 
energy values. 
 
Molecular mechanics can easily be regarded as a ball-and-spring model of atoms and molecules with 
classical forces separating them. The aforesaid forces can be considered by the potential energy functions 
concerning structural aspects being bond length, bond angle, and torsional angles. The potential energies 
are armed with parameters tailored to duplicate experimental qualities (Jaquet 2002). The total potential 
energy of a molecule is defined as the sum of bond-stretching energy (𝐸𝑠𝑡𝑟), the bond angle-bending 
energy ( 𝐸𝑏𝑒𝑛𝑑), torsion energy (𝐸𝑡𝑜𝑟) and energy of interactions between non-bonded atoms (𝐸𝑛𝑏). The 
energy contributions of the latter constitute van der Waals and electrostatic interactions, such that: 
𝐸𝑡𝑜𝑡 = 𝐸𝑠𝑡𝑟 + 𝐸𝑏𝑒𝑛𝑑+ 𝐸𝑡𝑜𝑟 + 𝐸𝑣𝑑𝑤 + 𝐸𝑒𝑙𝑒𝑐                                                                   (3.8) 
 
Where 𝐸𝑡𝑜𝑡 stands for the total potential energy, 𝐸𝑠𝑡𝑟 the bond-stretching energy, 𝐸𝑏𝑒𝑛𝑑  the bond angle- 
bending energy, 𝐸𝑡𝑜𝑟 the torsional energy, 𝐸𝑣𝑑𝑤 the van der Waals forces and 𝐸𝑒𝑙𝑒𝑐 the electrostatic 
forces separating atoms which are chemically non-bonded. Energy inputs from hydrogen bonding and 
stretch-bend pairing interactions are also explained in molecular mechanics. 
 
3.4.1 Force Field 
A force field is a mathematical framework, which describes complement of the energy of a system to the 
proportion of its particles. The commonly used sets of the parameter in bimolecular simulations are 
AMBER (Case et al. 2005), CHARMM, GROMOS (Christen et al., 2005), and NAMD (Fromageau et al., 2003) 
force fields. Customarily, parameters are captured from the data of experimental source, ab initio or semi-
empirical QM. Molecules are expressed as atomic sets held by elastic forces and the force field reduces the actual 
potential a plain model relevant to the area that is being simulated. A vast array of force fields is investigated 
each with a singular degree of intricacy and each set up to treat different kinds of systems. Different force fields 
have pros and cons analogous to the data and the implemented strategy in its framework, depending on selective 
malfunction at hand. Nonetheless, they ought to be adjusted to gain a global fitting; hence force fields gravitate 
towards showing similar results. Herein, the AMBER force field (Pearlman et al., 1995) was applied whereby 
the General AMBER Force Field was applied for the ligand and the standard AMBER force field to compensate 
for the protein. 
3.5 Molecular Dynamics 
Molecular dynamics (MD) is a computer simulation process for analyzing the kinetics of atoms and 
molecules. Properties of assemblies of molecules in terms of their structure and the microscopic can be 
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expounded using MD simulations. In MD, complex systems are modelled at atomic level and the 
equations of motion are mathematically solved to indicate the time of evolution of a specific system, thus 
allowing a derivation of its kinetic energy and thermodynamic properties through the application of 
computational tools (Peter Atkins, Julio De Paula 2009;Case et al. 2005). Atomic trajectories are 
generated through the integration of Newton’s equations of motion for atoms on an energy surface. This 
can be illustrated by the equation below: 
 
                             𝐹1=𝑚1 
𝑑2𝑟1(𝑡)
𝑑𝑡2
                                                                                                           (3.9) 
 
Where 𝑟𝑖  (𝑡) is the particle position vector, t is is time-evolution, m is the mass of the particle and𝐹1 depicts the 
interacting force on the particle. 
 
Molecular dynamics can be categorized into four (4) continuous technical steps that are repeated 
numerously to generate a trajectory. The categories can be summarized by: 
 
 
 
 
Figure 3.1: Cycle of molecular dynamics steps (prepared by author). 
The steps are outlined below: 
1) The fundamental requirements of the biomolecular system are defined: 
• The co-ordinates of each atom 
• The bond characteristics between each atom 
• The acceleration of atoms 
2) Each atom’s potential energy is computed. 
3) The energies from step are then utilized to solve the equation of motion. 
4) The new state of the system needs to be saved, and the atoms’ co-ordinates changed, and 
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step forward in the simulation taken. The cycle then restarts from step 1. 
 
3.5.1 Molecular Dynamics Post-Analysis 
 
Molecular post-dynamic techniques and calculations have been used to describe the protein features in 
studies conducted in this thesis. Molecular dynamic trajectories are a product of the run molecular 
dynamic simulation. They can be defined as sequential snapshots characterized by both positional co- 
ordinates and velocity vectors (Shao et al., 2007). In this study, post dynamic analysis of the trajectories is 
critical for determining the: 
1) Energetic and conformational stability of the biomolecular system. 
2) The characteristics of the system’s small molecule binding landscape and the 
thermodynamic energy fluctuations along the system’s clustered trajectory. 
3) Dynamic conformational features or variability of the biomolecular system. 
 
3.5.1.1 System Stability 
Convergence: 
Convergence is an empirical description of protein dynamics. It specifically describes protein 
dynamics based on bond types and bond angle vibrations during the unfolding of a protein. This fusion 
toward equilibrium and portrayal of a conclusive plateau is impertinent for a MD trajectory to be accurate 
and reproducible. At this plateau, the protein-ligand system displays energetically stable conformations 
(Galindo-Murillo et al., 2015) .  
Root Mean Square Deviation (RMSD): 
Spatial difference between two static structures of the same trajectory measure the deviation of a complex 
(Brüschweiler 2003). The RMSD of a trajectory is defined as: 
RMSD = 
∑ 𝑁 (𝑅1  − 𝑅1
0
𝑁
                                                                                                                      (3.10) 
 
 
Root Mean Square Fluctuation (RMSF): 
The root mean fluctuation (RMSF) of a protein measures residue’s Cα atom fluctuations is based on the 
average protein structure along the system’s trajectory. The RMSF captures the fluctuation for each atom 
around its average position (Margreitter & Oostenbrink,2017; Martínez, 2015). It is calculated using the 
equation below: 
 
sRMSF  =   
(𝑅𝑀𝑆𝐹1  − 𝑅𝑀𝑆𝐹)
𝜎(𝑅𝑀𝑆𝐹)
                                                                                       (3.11) 
Where: RMS𝐹1 is the RMSF of the ith residue, from which the average RMSF is subtracted. This is then 
divided by the RMSF’s standard deviation to yield the resultant standardized RMSF. 
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3.5.1.2 Binding Free Energy 
 
Binding free energy calculations are significant in ligand-polymer systems interactions and construction, 
and also in other facets of computational drug design discovery (Kollman 1993 ; Kamerlin et al., 
2009; Homeyer & Gohlke, 2012). Calculations of computer-based free binding energies of 
macromolecules and other differing molecular systems are estimated using either the Molecular 
Mechanics/Poisson-Boltzmann Surface Area (MMPB-SA) or Molecular Mechanics/Generalized Born 
Surface Area (MMGBSA) facilities (Wang et al. 2001; Kollman et al., 2000; Wang et al., 2006), which 
couple MM with the continuum solvation at low computational price (Wang et al., 2006). In the following 
studies, MMPBSA free energy calculations were used for differing molecular systems in question (Kar & 
Knecht, 2012). Additional explanation on free binding energy calculations has been described herein (see 
Chapters 3-4) 
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DOMP nanocrystals with particle size of 130 ± 3 nm. Moreover, the combination of 
hydroxypropylmethylcellulose and polyvinyl alcohol was also shown to be better in producing 
DOMP nanocrystals with smaller particle size (200 ± 3.5 nm). DOMP nanosuspension stored at  
2-8 ºC and room temperature (25 ºC) exhibited better stability compared to the samples stored at  
40 ºC. Crystallinity of the unprocessed and processed DOMP was monitored by Differential 
Scanning Calorimetry and Powder X-ray diffraction. DOMP nanocrystals gave enhanced 
dissolution rate compared to the unprocessed drug substance. DOMP nanocrystals at a dose of 20 
mg/kg in rats showed enhanced bioavailability compared to the raw drug substance and marketed 
formulation. A significant increase in plasma concentration of 2.6 µg/mL with a significant 
decrease in the time (1 h) to reach maximum plasma concentration was observed for DOMP 
nanocrystals, compared to the raw DOMP. Molecular modelling studies provided underpinning 
knowledge at the molecular level of the DOMP-polymer nanocrystal interactions and substantiated 
the experimental studies. This included an understanding of the impact of polymers on the size of 
nanocrystals and their associated stability characteristics.   
  
Keywords: Domperidone, Nanocrystals, Molecular modelling, Polymers, Dissolution; Enhanced  
bioavailability  
  
1. Introduction  
The oral route of administration is one of the most convenient,  useful and frequently used means 
to administer drugs (1). In this regard however, the poor aqueous solubility of drugs has been the 
leading factor, limiting the attractiveness of this route for some compounds and leading to low oral 
bioavailability and dissolution rate via this route. For drugs classified as class-II according to the 
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Biopharmaceutics Classification System (BCS), solubility and dissolution rate are of great 
importance and considered as the basic factors, which influence the rate and extent of drug 
absorption from GIT track (2). According to recent publications, approximately 40% of 
compounds in development are subject to poor water solubility (3). To reach the therapeutic plasma 
concentrations, poorly water soluble drugs are often given at high doses. With the variability in 
exposure, which is often observed for drugs of this nature, this provide risks of suboptimal efficacy 
and safety, particularly for drugs with low therapeutic index. In this regard, from a clinical 
perspective it is more desirable to use low doses of drugs having greater dissolution rate, better 
absorption and enhanced bioavailability. A number of well establishment strategies exist for 
enhancing the solubility and dissolution rates of drugs with low aqueous  
solubility.  (4, 5).   
In the current pharmaceutical drug delivery research domain, nanotechnology is an 
emerging field, where drugs with sub-micron particle size are increasingly being considered as a 
means to address the problem of poor aqueous solubility.. Owing to their significantly high  surface 
area to volume ratio, the nanoparticles (6, 7) are believed to provide an excellent means to drive 
dissolution in the GI tract. Noyes–Whitney equation gives a sound basis for this dissolution rate 
enhancement with reduction of the particle size to the nano-sized range, enhancing the surface free 
energy and surface area leading to increases in water solubility and rate of dissolution (8).  
In terms of methods for producing nanoparticulate drugs, two major techniques have been 
described, which include bottom-up and top-down methods. The typical top down methods include 
wet milling and high pressure homogenisation (9). Whereas, the bottom up methods are mainly 
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based on the principle of anti-solvent crystallisation (10). Nanosuspensions are the preparations 
composed of suspended particles in nanoform, stabilised by polymers and surfactants. The patented 
solvent displacement method was first used by Fessi et al for the preparation of nano suspensions 
(11).   
Domperidone is pharmacological antagonist of dopamine-2 receptor and belongs to class-II of the 
BCS (Biopharmaceutical Classification System) (Figure 1). DOMP is used as antiemetic as well 
as prokinetic representative by producing its effect on chemoreceptor trigger zone and also motor 
function of small intestine and stomach. This drug has poor aqueous solubility (0.986mg/L) while 
oral bio-availability is 12 to 18% percent during fasting and 24% after food  
(12). The poor water solubility seems to be one of the probable causes for its low bioavailability 
(13). The conversion of DOMP into stable nanocrystals could potentially be one of the promising 
solutions to address this issue.   
This study focused on the production of stable nanocrystals of DOMP and investigated using 
molecular dynamics simulation studies the polymer drug nanocrystal interactions underpinning use 
of the low energy antisolvent precipitation for nanocrystal manufacture. A number of studies have 
reported the impact of polymers on particle sizes of drug nanoparticles. Despite these learnings, 
the molecular level interactions of polymers and drug nanocrystals is still an interesting issue yet 
to be fully resolved (14). In this study, extensive molecular modelling was coupled with the 
experimental results to investigate and evaluate the correlation between molecular interactions and 
drug and stabilisers and nanoparticle properties. The traditional experiments cannot provide the 
molecular insight of the nanocrystal- polymer interactions in isolation. (15, 16). The 
comprehensive molecular level understanding gained from this study will be useful going forward 
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for nanoformulation scientists to optimise polymer selection for stable nanocrystals production for 
a range of different APIs.  
  
Figure 1: Chemical structure of Domperidone  
2. Materials and Methods  
2.1. Materials  
DOMP was gifted by Stanley Pharma having batch no. BDOM /1302036 Vasodha Pharma Chem 
Lab 78/A Vengal Rao Nagar Hyderabad-38 Andra Pardish India, ethanol and n-hexane china,Poly 
vinyl pyrrolidone (PVP) CAS number: 9003-39-8 and hydroxypropylmethylcellulose (HPMC) 
9004-65-3 USA were also gifted by Stanley Pharma. Sprague-Dawley rats (150-200 g) were used 
for bioavailability studies.    
2.2. Preparation of DOMP nanosuspension  
A low energy anti-solvent precipitation method was employed for production of stable nanocrystals 
of DOMP (14). The DOMP solution (10mg/ml) was prepared in  
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dimethylformamide (DMF)  then filled into the syringe and with the help of a syringe pump the 
solution was quickly injected at a constant flow rate of 2-8 mL/min into the polymer solutions that 
served as antisolvent phase, with continuous stirring rate at 600 -1000 rpm. Different polymers and 
subsequent t combinations thereof were used to evaluate their impact on produced nanocrystals of 
DOMP. The polymer solutions were composed of 1% (w/v) of each of the polymers which 
included PVP, Ethyl cellulose, HPMC and PVA, Pluronic F127, and Eudragit (EUD). Ethocel was 
dissolved in drug solutions in DMF then injected into the water. The produced DOMP nanocrystals 
were filtered and vacuum dried.   
2.3. Physicochemical characterization  
2.3.1. Particle size Measurements  
Particle size and associated polydispersity index (PI) measurements of the produced nanoparticles 
of DOMP were carried out in triplicate using dynamic light scattering (Zetasizer® NanoS, Malvern 
Instruments, UK), which measures the hydrodynamic diameter including the solvation layer 
around each particle.  
2.3.2. Morphological studies  
2.3.2.1. Scanning electron microscope (SEM)  
The principle used in the operation of scanning electron microscopy (SEM) is light reflection 
microscopy. Reflection of electrons occur as a result of incident light striking the surface of the 
powder sample and colliding with particle surfaces. The reflected electrons are picked up by the 
detector and are then transformed into an image by algorithm. Scanning electron microscopy is 
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applied for the description of surface morphology of the powder sample and provides good 
resolution down to scale of several nanometers.  
Surface morphology studies of the unprocessed DOMP was carried out by placing the sample on 
a grid covered with gold sputter coater (SPI, USA) using Jeol JSM5910 scanning electron 
microscope at an operating voltage of 30mA for duration of 2 minutes and an accelerating voltage 
of20Kv.  
2.3.2.2. Transmission Electron Microscopy (TEM)  
The size and appearance of the produced DOMP nanoparticles were evaluated using TEM  
(TEM-1200Ex; Japan Electron Optics Laboratory Corporation, Tokyo, Japan). The images of 
DOMP nanoparticles were taken at 120 kV. The drops of DOMP nanosuspensions were deposited 
on 200 mesh copper grid followed by coating with formvar/carbon (code no: S162) and drying at 
room temperature. Owing to low conductivity of the produced samples, they were negatively 
stained using 2% solution of magnesium uranyl acetate.  
2.3.3. Differential scanning calorimetry (DSC)  
To investigate and evaluate the impact of particle size on the thermal profile of the produced 
DOMP nanoparticles, the comparative DSC studies were carried out.  The samples were scanned 
using the Mettler Toledo Differential Scanning Calorimeter (MettlerToledo®, USA). Samples (2-
3mg) of unprocessed and processed DOMP were weighed into separate aluminium pans,  , which 
were sealed and then analysed  by heating from 30°to 300°C at a heating rate of 10°C min-1 and 
nitrogen flow of 40 ml/min. Indium was used as a standard for calibration of the instrument.  
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2.3.4. Powder X-Ray Diffraction Studies (PXRD)  
The prepared nanoparticles and unprocessed drug substance were subjected to testing for 
crystallinity using (PXRD) powder x-ray diffractometer (D8 ADVANCE, Bruker, Germany). The 
silicon-well sample holder was used for analysis of nanoparticle samples, while the plastic sample 
holder was used for raw drug substance. Nanaoparticle sample and raw drug substance were 
scanned in triplicate in the range 0o ≤ 2ϴ ≤ 70◦ using copper Kα as the radiation source with 1mm 
slit at 1.542 Å wavelength. Step size was 0.05◦ and the time lapse between the steps was 2 seconds.  
2.4. Stability studies  
The stability of nanoparticles, particularly those produced by bottom up method is very important, 
especially because agglomeration and particle growth can occur quickly, leading to the loss of 
rapid dissolution performance. In this study, produced DOMP nanosuspensions was subjected to 
testing of physical stability over a duration of 90 days following storage at 2-8°C, 25°C and 40 ºC.   
This study was designed to monitor the rate and extent of particle growth with measurements of 
particle size being made using dynamic light scattering.     
  
2.5. Computational methods  
2.5.1. Molecular Docking of polymers and DOMP   
A short MD run was performed on the polymers to obtain relaxed energy conformers prior to 
docking. The Molecular docking software utilized included Raccoon (17), Autodock Graphical 
user interface supplied by MGL tools (18) and AutoDockVina (19) with default docking 
parameters. Prior to docking, Gasteiger charges (20) were added to polymers as well as 
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Domperidone and the non-polar hydrogen atoms were merged to carbon atoms. The gridbox was 
set to cover the entire polymer to allow for the best-docked pose. The optimal geometric 
conformation bearing the best binding energy was picked from the View Dock feature on 
Chimera(21) and the complex saved with the reference polymers.  The polymer-domperidone for 
each system was prepared using Chimera and MMV molecular modeling suites (22) and later 
subjected to molecular dynamic simulations.  
2.5.2. Molecular Dynamic Simulations  
GPU version of the PMEMD engine in Amber14 software package was utilized to execute 
unrestrained all-atom MD simulations. The Restrained Electrostatic Potential (RESP) and the 
General AMBER Force Field (GAFF) (23) systems were used by ANTECHAMBER (24) to 
generate the atomic partial charges for the polymers and domperidone. The systems were solvated 
in a cubic box of TIP3P water, such that all atoms were within 10 Å of a box edge. Long-range 
electrostatic interactions were treated with the Ewald method and a van der Waals cut-off of 12 Å. 
Each of the systems were minimized for 1000 steps (500 steepest descent followed by 2500 steps 
of the conjugate gradient). The langevin thermostat, with a collision frequency of 1.0 ps-1 with 
harmonic restrained of 5 kcal/mol on the solutes, was applied during the gradual heating of the 
systems to a temperature of 300 K in the canonical ensemble for 50 ps. This was followed by 50 
ps of density equilibration in NPT ensemble and a final 500 ps equilibration at 300 K, 1 bar pressure 
and a coupling constant of 2 ps, and the by a MD production run of 50 ns. System coordinates were 
then saved every 1 ps and analyzed using the PTRAJ module employed in AMBER14 (25) . The 
Root mean square deviation (RMSD) was  
employed to establish the stability of the 12 systems over the 50 ns trajectory.   
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2.5.3. Binding free energy calculation  
Calculations of free binding energies were engaged using the Molecular Mechanics/GB Surface  
Area method (MM/GBSA) (26) . This was carried out to evaluate the binding affinities of each 
system. Binding free energies were then averaged over 5 000 snapshots extracted from the 50 ns 
trajectory. Figure 2 depicts free binding energy (ΔG), which was computed by the MM/GBSA 
method for each molecular species (complex, ligand and polymer).  
  
  
  
  
Figure 2: Diagrammatic representation of thermodynamic calculation (MM/GBSA) used in the 
study (Prepared by Author)  
  
2.6. Bioavailability studies  
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The pharmacokinetics studies of unprocessed domperidone, its fabricated nanocrystals 
(DomNano), prepared solid dosage form (Dom-Nano dosage form) and marketed formulations 
were carried out using rats as the animal model. Sprague-Dawley rats (150-200 g) were 
administered with an oral dose of 10 mg/kg of domperidone, its nanoparticles, its nano-dosage 
form, and marketed drug and blood was collected after 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hrs 
postadministration (n = 6 rats each for different time periods). The collected blood samples were 
centrifuged and plasma was obtained. The blood plasma was quanitified for DOMP using a 
reported HPLC method (27). The pharmacokinetics parameters in the plasma were determined 
using the pharmacokinetic software WinNonLin (v 4.0; Pharsight Software, Mountain View,  
CA, USA). The pharmacokinetics parameters determined includemaximal plasma concentration 
(Cmax), time to reach maximalplasma concentration (Tmax), half-life (t1/2), and the area under the 
concentration-time curve (AUC).  
2.7. Dissolution studies  
Dissolution studies on pure DOMP as well as the nanoparticles prepared EPN was performed using 
two separate dissolution tests, both using the U.S. Pharmacopoeia (USP) tablet dissolution test 
apparatus 2 (6 station) with the  paddle  rotating  at  50  rpm  in  900  ml  of both pH  1.2  (0.1N  
HCl)  media and  in a separate test 6.8  pH  phosphate  buffer   at 37±0.5°C. All drugs equivalent 
to 10 mg of DOMP were used as samples for the dissolution test. At 10 min, 30 min and 60minutes 
intervals, 5  ml samples were withdrawn,  filtered through a 0.1 nm  membrane  filter and assayed  
for DOMP content by measuring the absorbance at 284 nm using UV -Visible spectrophotometer  
(Shimadzu  UV-1700).  Fresh medium (5 ml), pre-warmed at 37±0.5°C, was added to the 
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dissolution medium after each sampling to maintain a constant volume throughout the test. 
Dissolution studies were performed in triplicate (n=3) [15].  
2.8. Statistical analysis  
All the tests were run in triplicate and results were given as mean± standard mean error (SEM). 
Mean values were compared using Anova-test and differences were considered statistically 
significant at level (p < 0.05) using Statistics 8.1 software.  
3. Results and discussion  
3.1. Preparation of DOMP nanosuspension using antisolvent precipitation method  
Nanosuspensions of DOMP were produced by antisolvent precipitation. The particle size of 
nanosuspensions produced using this method are given in Table 1. There were used different 
polymer solutions as anti-solvent phase having different combination of polymers to investigate 
the impact of the polymers on particle sizes of the produced DOMP nanocrystals. There was 
observed that Ethocel was the most suitable single polymer to produce DOMP nanocrystals with 
small particle size 130.0±3.0 (Table 1 and Figure 3). This shows that ethocel strongly adsorbed 
onto the surface of DOMP nanocrystals to establish the steric stabilisation with subsequent small 
particle size and low PDI value. In addition, HPMC was also found comparatively effective single 
polymer to control the size of DOMP nanocrystals (300±4.0) (Table 1). However, when HPMC 
was combined with PVA in antisolvent phase, the impact became more predominant in terms of 
controlling the particle size. The combination of HPMC-PVA produced DOMP nanocrystals with 
particle size (200± 3.5). DOMP nanoparticles produced at optimised conditions were quickly 
recovered by vacuum evaporation of all solvent and antisolvent using a rotary evaporator and were 
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the washed and dried. The resulted PDI was was below 0.5, which shows homogenous particle size 
distribution of the suspended particles (28, 29).   
Table 1. Impact of polymers on particle sizes and PDI values of DOMP nanosuspension.  
DOMP-Polymer 
complexes  
Particle 
size ± SD  
PDI ± S.D  
Ethocel  130.0±3.0  0.15±0.01  
Pluronic  1200±7.5  0.85±0.06  
PVP  950.0± 5.0  0.77 ±0.05  
PVA  400.0± 4.5  0.50 ± 0.03  
EUD  1175±7.0  0.80±0.06  
HPMC  300±4.0  0.40±0.02  
EUD-PVA  775± 6.0  0.65±0.04  
EUD-PVP  985± 5.7  0.80±0.05  
HPMC-PVA  200±3.5  0.20 ±0.02  
HPMC-PVP  570.0± 5.0  0.52 ± 0.03  
HPMC-EUD  550± 6.5  0.60±0.04  
PVA-PVP  650± 5.2  0.40±0.02  
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Figure 3: Particle size distribution of DOMP nanoparticles.  
  
The highly concentrated drug solutions injected into anti solvent phase can potentially produce 
high levels of supersaturation and consequently nanoparticles with small particle size. The (SAS) 
ratio is a very important process parameter, which should be optimised during APSP production 
of nanoparticles, whereby the barrier for the existing species to be grown during mixing of the 
solvent anti-solvent phases is affected by this parameter. In this study, it has been observed that 
DOMP nanoparticles with small particle size (130.00nm ± 3.0) were produced using a high SAS 
ratio (Figure 3), while using the antisolvent phase with etocel.  At low SAS ratio the available 
diffusion distance for the growing species is low and can potentially lead to high nucleation with 
subsequent comparatively large particle sizes being produced (30, 31).   
  
  
3.2. Morphological examination  
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The morphology studies of raw and processed DOMP were carried out by SEM and TEM 
respectively. SEM observation showed some differences in size and shape of the unprocessed 
DOMP particles (Figure 4 (A)). The average particle size was found to be 10-15 micron and most 
of the particles were shown to be cuboidal and prism like. Some traces of oval shape particles were 
also observed although, all particles are appeared to demonstrate regular crystalline morphologies 
(Figure 4 (B)). TEM images of the DOMP nanoparticles demonstrated that most of the particles 
were spherical in shape with some traces of the triangular shape particles. In addition, the TEM 
results exhibited that all the nanoparticles were homogenously distributed with no clumps or 
aggregates. The particle size was shown to be approximately 100.0nm in good agreement with 
DLS data. The minor difference in the particle size measured using DLS and TEM is related to the 
difference in the principles of the two techniques. In DLS, the electrical double layers surrounding 
the individual particle could are also measured, whereas,  
TEM only measures the actual particles (29).    
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Figure 4.  SEM image of raw DOMP (A) and TEM micrographs of processed DOMP particles (B)  
  
  
  
  
3.3. PXRD analysis  
PXRD analysis was carried out for raw and DOMP nanoparticles. PXRD diffractograms show that 
raw DOMP sharp peaks of high intensity compared to the DOMP nanoparticles (Figure 5 A). The 
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nano formulation gives lower intensity, broader peaks, which are typically of crystalline particles 
with low particle size peaks (Figure 5 (B)). X-ray diffractograms with lower peak intensities and 
the absence of some peaks have also been previously been reported by other researchers for 
crystalline nanoparticles (32-34). Furthermore, nanoparticles can result in broadening and 
disappearance of some peaks in X-ray diffractograms. Owing to small angular reflection by the 
smaller particles, the peak intensity of X-ray diffractograms is reduced. For domeperidone 
nanoparticles, the small sample sizes were with fewer particles can also result in lower intensity 
reflections.   
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Figure 5:  PXRD patterns of Unprocessed (A) and DOMP nanoparticles (B).  
  
 3.4. DSC analysis  
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DSC thermograms of pure DOMP and the prepared nanocrystals are shown in Figure 6. There 
appeared an intense endothermic peak at approximately 238ºC for unprocessed DOMP. It is known 
that crystalline structure will give a peak at the melting point temperature with high heat enthalpy 
(ΔH) values compared to that of amorphous structures of the same materials. The produced 
nanocrystals have low values of the ΔH representing reduction in crystallinity of the resulted 
nanocrystals. The produced nanocrystals have shown melting point peak at lower temperature 
compared to the unprocessed DOMP, which is typical of nanocrystalline materials.  
The endothermic peak of the processed DOMP was broadened, which is potentially be caused by 
the packing density of the produced nanoparticles, incorporating traces of stabilising polymers 
(35).   
  
Figure 6: DSC Thermograms of Unprocessed DOMP and DOMP nanocrystals.   
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3.5. Molecular docking and conformational analysis of polymer systems   
Molecular docking is a conventional method in computational chemistry, which is utilized in the 
prediction of optimized geometric conformations of a ligand within an appropriate binding site 
(36). Of the docked polymer-DOMP complexes (Figure 7 and 8), the highest binding affinity was 
observed for the HPMC-EUD co-polymer (-6.0 kcal/mol). Of the mono-polymer complexes, PVP 
demonstrated the highest binding affinity (-5.2kcal/mol).  
  
  
Figure 7: Binding affinity results from molecular docking of domperidone-monopolymer 
complexes.  
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Figure 8: Binding affinity results from molecular docking of domperidone –copolymer complexes.  
  
  
The molecular docking results, however, only take into account  the geometric orientation of 
domperidone when bound to suitable regions of the polymers and thus may be inconclusive when 
identifying the forces that stabilize domperidone to the polymers. To overcome any binding mode 
abuiquities, molecular dynamics were carried out to simulate the interaction of domperidone with 
the polymers over a 50ns trajectory. After allowing domperidone to equilibrate with the polymers, 
the binding mechanism and stabilizing intra-molecular forces were investigated using binding free 
energy calculations.   
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3.6. Polymer systems stability through molecular dynamic simulations   
The stability of trajectories that was identified using root mean square deviation (RMSD) over the 
50ns simulation, the potential energy of the polymer-domperidone remained stable during the MD 
trajectories and convergence was reached at approximately 20ns.   
3.7. Thermodynamic energy analysis   
The total binding free energy for each of the 12 polymer-domperidone complexes were calculated 
using the MM/GBSA approach to better understand the various energy contributions stabilizing 
the polymer to domperidone and to assess which polymer-complex showed the most favorable 
intermolecular interactions. Based on Table 2, a conformational analysis was performed to 
distinguish between the most favorable polymer-domperidone complexes.  
Calculating the thermodynamic energy between a polymer and drug gives the approximate 
intensity and stability of interactions between the molecules, thus a higher binding interaction will 
result in a more stable polymer-drug complex (37).  
1 Table 2.   Binding free energy analysis (kcal/mol) for polymer-domperidone complexes.  
2    
3    
Energy Components (kcal/mol)  
4    
Single Polymer Systems 5    
Complex   Δ EvdW   ΔEelec   ΔGgas  ΔGsolv   ΔGbind 6   
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Ethocel   
Pluronic   
PVP   
PVA   
EUD   
HPMC   
 -30.37 ± 0.24 
-3.69 ± 0.05   
-5.52 ± 2.68   
-31.77 ± 5.23   
-4.10 ± 2.09   
-20.35 ± 0.92   
    -6.95 ± 0.43  -37.32 ± 0.43 10.06 ±0.33  -27.26±0.247    
0.29 ± 0.079   -3.40 ± 0.96 2.19 ± 0.09  -1.20 ± 0.54
8  
  
9   
-20.94 ± 1.12 -26.46 ±1.87 18.75 ± 0.52 -7.72 ± 1.95  
10   
-25.19 ± 11.32 -56.96 ± 12.24 38.08 ± 8.33 -18.88 ± 
6.39 11   
-5.55 ± 0.60   -9.64 ± 1.84 7.73 ± 0.31    -1.91± 1.9712   
-22.42 ± 0.79   -42.77 ± 1.04 20.04 ± 0.43 -
22.73±0.8213    
14   
           
  Dimer Systems    15   
Complex   Δ EvdW   ΔEelec  ΔGgas   ΔGsolv   ΔGbind16      
 
EUD-PVA -13.83 ± 0.34  0.00 ± 0.00  -13.83 ± 0.34 4.33 ± 0.10 -9.50 ± 0.3617     
EUD-PVP -10.78 ± 0.73 -5.08 ± 0.43 -15.87 ± 0.56 9.19 ± 0.33 -6.67 ± 0.6418     
HPMC-PVA -39.84 ± 0.74 -12.88 ± 0.85 -42.72 ± 1.00 17.50 ± 0.62 -25.22 ± 0.79  
HPMC-PVP -15.15 ± 1.37 -24.91 ± 0.71   -40.06 ± 1.19 24.46 ± 0.44 -15.60 ± 1.13  
HPMC-EUD -13.17 ± 0.81 -27.93 ± 0.78 -41.10 ± 0.85 27.00 ± 0.40 -14.10 ± 0.84  
PVA-PVP -26.09 ± 1.23 -12.77 ± 1.11 -28.86 ± 1.53 16.09 ± 0.56 -12.77 ± 0.60  
Upon analysis of Table 2, the most favorable interactions were observed in the Ethocel system (- 
27.26 kcal/mol), while the Pluronic complex showed the least favorable binding free energy (1.20 
kcal/mol). It was also interesting to note that the inclusion of EUD significantly lowered the 
thermodynamic energy of the co-polymer complexes, as the addition of EUD to PVA decreased 
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the free binding energy by 9.38 kcal/mol. This trend was also observed in both the HPMC and PVP 
complexes.  This confirms that molecular docking demonstrates only the “geometric fit” of two 
molecules and free energy binding calculations are still required when estimating molecular 
interactions (38). As observed in the HPMC-PVA complex, significant improvements were noted 
in the thermodynamic energy upon inclusion of HPMC compared to the monopolymer PVA 
complex (Figure 9 and Figure 10). This may have been a result of increased intermolecular surface 
area based on the interaction size of HPMC. The above characteristic features may also be used to 
explain the high binding energy of the Ethocel complex (Figure 11). Increased molecular surface 
area due to the conformational flexibility of Ethocel may have allowed for greater hydrophobic 
interactions with domperidone. As a general trend, greater stability was seen in the polymers that 
showed enhanced interactive binding surfaces such as HPMC and Ethocel.   
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Figure 9: The lowest energy conformation of HPMC-PVA-DOMP complex (-25.25 kcal/mol); (A) 
depicts the molecular surface of HPMC-PVA encapsulating DOMP, (B) displays the hydrogen 
bond interaction between DOMP and HPMC.   
  
  
  
Figure 10: The PVA-DOMP complex (-18.88kcal/mol) (A) Molecular surface interaction between 
PVA and DOMP, (B) graphical representation of the lack of hydrogen bonds between PVA and 
DOMP.  
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Figure 11: The lowest energy conformation of Ethocel-DOMP complex (-27.26kcal/mol) after 
molecular dynamic simulations; (A) molecular surface interaction between Ethocel and DOMP, 
(B) presents three stabilizing hydrogen bonds of the Ethocel-DOMP complex.  
  
3.8. Bioavailability studies  
The pharmacokinetic profile of domperidone in plasma after oral administration of 10mg/kg dose 
of DOMP, its nanocrystals, tablets having DOMP in annoform and marketed product (Motilium®)  
via oral administration is shown in Figure 12.   
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Figure 12: Comparative in-vivo Pharmacokinetic profile of (Domperidone) (n = 6, ±SD) **P < 
0.01, ***P < 0.001.  
  
  
Numerious pharmacokinetic parameters, including area under the concentration-time curve, 
maximal plasma concentration, time to reach maximal plasma concentration, and biological 
halflife, are shown in Table 3.  
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     Table 3: Summary of pharmacokinetic parameters for domperidone.  
Sample  Pharmacokinetic Parameters  
T1/2 (h)  Tmax (h)  Cmax (µg/mL)  AUC0-t (µg h/mL)  
Raw DOMP  4.182±0.43  2.0±0.11  1.3±0.26  4.91±0.31  
DOMP      
Nanocrystals  13.34±0.32***  1.0±0.07**  2.6±0.18**  13.3±0.44***  
Tablets      
(DOMP- 
Nanocrystals)  
8.334±0.71***  1.0±0.09**  2.4±0.21**  11.3±0.39***  
DOMP      
marketed 
formulation  
6.451±0.52*  2.0±0.16  1.6±0.31  7.73±0.37*  
  
(n = 6, ±SD) *P < 0.05, **P < 0.01, ***P < 0.001  
  
  
Administration of domperidone at a dose of 20 mg/kg showed an elimination phase from 10 to 12 
h with an elimination half-life of 4.18 h with a clearance of 4051.3 mL/h. The distribution phase 
was observed from 6 to 8 h with an observed volume of distribution of 24470.8 mL.The absorption 
phase was noted from 0.3 h to 4 h. The maximum plasma concentration was observed as 1.3 µg/mL 
at 2 h. 4.9 µg h/mL was the area under the concentration-time curve from time 012 h. Marked 
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changes in the pharmacokinetics of nanoparticles were observed. Administration as nanoparticles 
increased the plasma concentration of domperidone throughout the study; however, a noteworthy 
escalation has been noted at 0.5 h (P< 0.01), 1-2 h (P< 0.001) and at 4 h (P< 0.05). The 
nanoparticles formulations resulted in a decreased elimination rate of domperidone as reflected 
from a significant increase in the half-life of 13.34 h (P< 0.001). A significant increase plasma 
concentration of 2.6 µg/mL (P< 0.01) with a significant decrease (P< 0.01) in the time (1 h) to 
reach maximum plasma concentration was observed compared to domperidone treated rats. The 
nanoparticles increased the plasma exposure of domperidone as a significant increase in the AUC 
from time zero to 12 h was observed (13.3 µg h/mL, P < 0.001). Similarly, the nano dosage form 
also showed an enhancement in the pharmacokinetic parameters i.e. half-life (8.3 h, P< 0.001), 
maximal plasma concentration (2.4 µg/mL, P< 0.01), time to reach maximal plasma concentration 
(1.0 h, P< 0.01) and AUC (11.3 µg h/mL, P< 0.001), as compared to domperidone treatment. For 
the marketed drug, a significant increase in the appararent half-life (6.45 h, P< 0.05) and AUC 
(7.73 µg h/mL, P< 0.05) was observed compared to the domperidone alone treated animals  
  
3.9. Stability studies  
The physical stability studies of DOMP nanosuspensions stored at 2-8 ºC, 25 ºC and 40 ºC for 90 
days showed  that nanosuspensions stored at 2-8 ºC and 25 ºC (Figure 13A and 13B) were stable 
compared to the samples stored at 40 ºC (Figure 13C). The nanosuspension stored at 2-8ºC 
exhibited adequate stability (Figure 13A) with no marked changes in key nanosuspension 
characteristics. The nanosuspensions stored at 2-8 ºC and 25 ºC maintained their PDI values and 
there was no significant difference (P>0.05, paired t-test, one way ANOVA) difference in the 
mean values of particle size after 90 days storage, which confirms that a homogenous particle size 
 
62  
  
distribution of DOMP nanocrystals has been achieved and consequently the Ostwald ripening 
process which is very common in the nanosuspensions could be hindered.   
Among the different factors influencing physical stability of nanosuspensions, temperature has 
been reported the major factor to be controlled for production of stable nanoparticles (14, 39).  At 
high temperature, kinetic energy of the suspended particles increases which results in strong van 
der Waals forces and increased attraction among the particles followed by agglomeration and 
destabilisation of the suspensions. For maximum stabilisation of nanoparticles, a temperature range 
of 2-8ºC has been recommended by Frietz and Muller.In addition, increases in temperature and 
high intensity of light radiation can cause rapid particle growth. Nucleation is the key step in anti-
solvent crystallisation methods which can be manipulated for tailoring particle size and shape of 
crystallised materials (40, 41). Moreover, the polymeric media and associated stabilising agent is 
also considered very important and is known to facilitate surface stabilisation and consequent 
control of particle size during the nucleation process (42). 0.5% ethocel was found the most suitable 
single polymer to effectively control the growth of the DOMP nanocrystals, which remained stable 
for 90 days (Table 4).  This study demonstrated that sufficient adsorption of the polymers occurred 
onto the surfaces of the produced DOMP nanocrystals which resulted into strong repulsion of the 
particles and subsequent colloidal stabilization. The molecular Modeling studies also substantiated 
the experimental results and suggested that Ethocel gave higher binding free energy (-27.26±0.24 
kcal/mol) compared to other complexes which in turn provided higher levels of surface polymer 
adsorption and more effective stabilisation. In addition, DOMP nanocrystals produced by 1% 
HPMC were also shown to be stable compared to other single polymers. This binding free energies 
resulted for DOMP nanocrystals and HPMC (-22.73±0.82 kcal/mol) also suggest that HPMC could 
be effectively adsorbed onto the surface of DOMP nanocrystals with subsequent controlled particle 
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growth.  In the case of polymer combinations, the combination of HPMC-PVA was found the most 
suitable combination to retard the particle growth, because of its higher binding free energy (-
25.22±0.79 kcal/mol) compared to other counterparts.  
  
  
  
  
  
  
  
  
  
  
  
  
  
Table 4:  Stability study of DOMP optimised nanocrystals as a function of time.  
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DOMP-polymer 
complexes  
Average Particle Sizes of DOMP Nanocrystals with ± SD   
Day 0  Day 15  Day 30  Day 45  Day 60  Day 75  Day 90  
Ethocel-DOMP  130.0±2.5  135±3.0  140±4.0  143±3.5  144±4.5  145±3.8  147±3.5  
Pluronic-DOMP  1200±4.5  1280±5.0  1385±3.5  1450±4.5  1600±5.5  1730±6.5  1850±6.0  
PVP-DOMP  950.0± 5.0  980±5.5  1070±6.0  1200±4.5  1280±4.0  1390±7.0  1470±7.5  
PVA-DOMP  400.0± 4.5  440±3.0  455±2.7  470±3.2  490±2.4  520±3.5  545±2.8  
EUD-DOMP  1175±7.0  1220±3.7  1260±3.5  1325±3.7  1410±2.5  1500±2.0  1610±3.0  
HPMC-DOMP  300±4.0  325.0±2.0  338±2.7  350±2.0  370±3.0  385±3.5  392±2.5  
EUD-PVA-DOMP  775± 6.0  800±5.4  860±5.5  930±4.0  1020±6.4  1100±5.6  1170±6.0  
EUD-PVP-DOMP  985± 5.7  1015±6.5  1090±5.5  1210±7.0  1300±6.5  1410±7.5  1515±5.8  
HPMC-PVA-DOMP  200±3.5  210±2.5  217±2.0  230±2.4  240±3.0  245±2.7  250±2.5  
HPMC-PVP-DOMP  570.0± 5.0  600±2.8  645±3.5  680±3.0  730±3.7  790±3.0  830±3.2  
HPMC-EUD-DOMP  550± 5.5  575±4.5  615±5.0  650±4.0  690±4.5  710±5.5  750±6.0  
PVA-PVP-DOMP  650± 5.2  695±5.5  730±6.0  780±6.5  830±5.0  900±4.5  945±6.5  
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Figure 13: Stability studies of DOMP nanoparticles stored at 2-8 ºC (A), 25 ºC (B) and 40 ºC.  
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3.10. Dissolution studies   
Figure 14 clearly shows that dissolution of DOMP has been increased enormously with the 
conversion of pure/raw DOMP to the nanocrystals prepared by EPN method. The difference in 
dissolution profiles of the produced DOMP nanocrystals forms in acidic and basic media is 
attributed to its physicochemical attributes. DOMP is basic in nature, therefore it dissolves 
efficiently in acidic media; [23]. The dissolution study of DOMP conducted in a buffer (pH 6.8) 
medium resulted in approximately 80% and 20% release of the drug within first ten minutes, from 
nanocrystals and raw DOMP formulations respectively. In addition, the dissolution studies 
conducted at acidic pH (0.1M HCL), also resulted in enhanced dissolution rate for DOMP 
nanocrystals (38%) compared to the raw DOMP.  Dissolution has been reported as being the rate 
limiting step for BCS II class drug compounds, because they have high permeability but low 
dissolution rate (43). Owing to increased dissolution rate of DOMP nanocrystals, the 
bioavailability could also potentially be enhanced, which is substantiated by the oral bioavailability 
studies in rates.  Furthermore, nanocrystals have increased surface area and improved adhesiveness 
to the cell membrane which subsequently leads to high bioavailability (44). The dissolution studies 
confirmed that the produced DOMP nanocrystals maintained their surface area and particle size.   
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Figure 14: Comparative dissolution profile of unprocessed and DOMP nanoparticles at acidic pH: 
0.1MHCL (A) and phosphate buffer pH: 6.8 (B).  
  
  
(  A  )  
(  B  )  
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4. Conclusion  
This study concluded that polymers play an important role in the production of stable nanocrystals 
using the anti-solvent precipitation method. This study provided molecular insight into the 
interactions between polymers and drugs at nanocrystal surfaces, knowledge which is not easily 
accessible through experiment. Ethocel was found the most effective polymer to control the 
particle size of DOMP nanocrystals (130.0 ± 2.5). Furthermore, the 1% (w/v) HPMCPVA 
combination also showed strong binding potential with DOMP nanocrystals demonstrating particle 
size (200.0±3.5). The molecular modelling studies provided molecular level insight into polymer 
drug interactions underpinning the mode of binding of polymers with DOMP at the surfaces of 
nanocrystals. This has provided an opportunity for the formulation scientist to rationally select 
suitable polymers, most likely to achieve desirable particle size control for nanocrystals and deliver 
stable formulations which deliver optimal in-vivo performance.    
DOMP nanocrystals showed enhanced dissolution rate at both acidic and basic pH conditions 
compared to the unprocessed form of DOMP. The dissolution enhancement for this BCSII class 
drug compound can potentially provide the opportunities to develop a more cost effective dosage 
form having the same therapeutic performance, but at much lower dose compared to the existing 
marketed drug product. Pharmacokinetic studies in rat have shown that the improved dissolution 
performance leads to markedly improved rate and extent of drug absorption in-vivo. Future studies 
will be focussed on transforming the prototype formulations tested in this project into drug 
products suitable for clinical testing and commercialisation.   
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 Abstract  
Parkinson’s disease is marked by gradual loss of dopaminergic neurons and embodies an escalated health 
encumbrance, particularly in developed countries. Most clinically approved drugs used in Parkinson’s 
treatment are specifically utilized for symptomatic relief and/or are associated with a plethora of adverse 
effects. The rarity of curative or effective treatment for Parkinson’s in the medical sector is the key 
motivation of the growing studies for therapeutic alternatives. Currently a concoction of drugs shuttled by 
polymeric nanoparticles has proven advantageous. These “drug carriers” have recently sparked interest in 
the pharmaceutical domain due to increasing popularity in overcoming two common adverse effects of brain 
diseases:  off-target binding and inability to pass the blood-brain-barrier. This study seeks to unravel some 
of the In-silico methodology that can be used to improve potential compounds and establish varying drug-
polymer combinations that can traverse the blood brain barrier and bind effectively at a target site. The 
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establishment of this computational approach as a blueprint in increasing bioavailability and reducing 
adverse of anti-Parkinson’s drugs will eventually prove useful in other neurodegenerative diseases.     
Introduction  
Parkinson’s disease (PD) is the second most common neurodegenerative disease devastating approximately 
1-1.5% of the populace above 60 years old. At present the degenerative onslaught of PD cannot be cured 
(Leyva-Gómez et al., 2015). The difficulty of attaining curative therapy could be attributed to the 
complexity of its etiology. There are other highly efficient non-pharmacological treatments like deep brain 
stimulation (DBS) of the subthalmic nucleus (STN) with known curative potential and chance of side effects 
and surgical risks. However, our supreme focus will be pointed on pharmacological treatment of PD, whose 
potentiality is yet to be fully explored. The PD drugs that are available in the realm of approved medicines 
only replenish, regulate and imitate dopamine effects and alter motor behavior in varying ways. The 
dopamine precursor, Levodopa (L-dopa) is a gold standard that is renowned for its ability to improve the 
quality of life among PD patients.  Levodopa/Carbidopa (Levocarb) formulation is the foremost treatment 
for PD symptoms. Yet contrary to its “golden” abilities, this dopamine precursor like other antiparkinsonian 
drugs as dopamine agonists, monoamine oxidase type B (MOA-B) inhibitors, amantadine and domperidone 
have differing adverse effect. It is these dilapidating effects and many drugs with limited solubility that have 
necessitated the in-silico investigating the approach for improvement of efficacy by modifying the structure 
and using novel drug delivery systems as polymeric nanoparticles (Loftsson and Brewster, 2010).  
  
Usually symptoms of PD are akin to motor functions because dopamine is essential for conveying electrical 
signals for sustaining normal physical motion (Hovgaard and Brndsted, 1995). At initial stages of PD, the 
most commonly seen symptoms are movement-related such as bradykinesia, resting tremor, rigidity, and 
postural instability (DeMaagd and Philip, 2015; Silindir Gunay et al., 2016). As the disorder develops, 
thinking and behavioral problems may arise, and dementia can occur in the advanced stages of the disease 
(Hovgaard and Brndsted, 1995) . Additionally, depression can be seen as a psychiatric.   
  
The “Degenerative” Origin of PD  
Parkinson’s disease results mainly due to complications of the basal ganglia, which mainly enables muscle 
tone, and ease of movement. This degeneration of the substantia nigra, essentially the loss of neurons in the 
 
78  
  
pars compacta of the substantia nigra results in reduced dopamine levels (Figure 1) cause the striatum fire 
out excessive unwanted signals namely tremors, which are most basic symptoms of Parkinsonism (Newland 
et al., 2015) .  
  
  
Figure 1: Pathologic degeneration of the dopamine pathway during Parkinson’s disease. Decreased 
dopamine levels lead to staggered or minimal excitement through peripheral neurons, thus resulting in 
movement disorders (created by Authors).  
  
 Deterioration in basal ganglia in the brain of PD patients fundamentally influences dopaminergic neurons 
in the substantia nigra, which concludes in dopamine insufficiency. In PD, the dyed neurons of the 
substantial nigra, locus caeruleus and other brain stem dopaminergic cells are vanished therefore reducing 
the production and transfer of dopamine within the nigrostriatal pathway. The death of neurons in the 
midbrain area is also closely linked with the formation of Lewy bodies which are strange proteins which 
develop inside nerve cells (Leyva-Gómez et al., 2015).  
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The “Degenerative” Origin of PD  
The substantia nigra is depigmentation, neuronal loss and gliosis (within the substantia nigra). Pathogenesis 
probably involves apoptosis and necrosis of dopaminergic neurons. The death of neurons is supposedly due 
to protein misfolding, aggregation and toxicity, defective proteolysis, mitochondrial dysfunction or 
oxidative stress thus reduces dopamine. Other pathological hallmarks are Lewy bodies within the soma of 
the neurons, which are mainly made up of α-synuclein bound to ubiquitin and other proteins (Leyva-Gómez 
et al., 2015).    
  
Treatment Regimens Against Parkinson’s Disease: A Major Gap in Effectivity   
Presently, the variable treatment regimens endorsed for PD only present with symptomatic aid of sufferers. 
Therefore deemed incurable to inability to halt or attain reversal of the neurodegenerative progression 
(Schapira et al., 2014). The motor indicators are managed by a plethora of compounds that boost the DA 
level in the central nervous system (CNS) or mimic its effects. A DA precursor, namely, Levodopa for years 
now has been recognized as the gold standard for the treatment of PD. Additional regimens popularly 
recommended are DA receptor agonists, monoaminoxidase (MAO) 1 inhibitors (such as selegiline and 
rasagiline), amantadine, catechol-o-methyl-transferase (COMT) inhibitors and anticholinergic agents. 
These medicines are expected exert their effects of   reducing symptoms to better patient lifestyle until a 
cure is discovered (Esposito et al., 2007).  
Table 1 shown below shows some of the medicines that are already in the market or still undergoing clinical 
tests due to their potential antiparkinsonian effect. As highlighted earlier these drugs merely   treat motor 
symptoms and non-motor symptoms which have devastating effects in individual, their life style and the 
general economy due to its implications on people who are part of a nation’s due to the demand on the 
public sector and tax payers to take care of PD related costs and supply (Kowal et al., 2013). Although there 
are ample treatment regimens for PD, none are fully effective while some have major adverse effects. 
Available treatment against PD is largely symptomatic since no drug has been found to slow down the 
degenerative process or worse even cure the disease.   
This is because limited insight into the disease progression has been gathered. The most significant drug 
against the motor symptoms is levodopa. Even though it’s long term administration is known to induce 
motor complications the pro-drug is still the gold standard for symptomatic treatment, being the most 
tolerated among dopaminergic remedies (Silindir Gunay et al., 2016). Dopamine agonists have shown to 
have anti-parkinsonian activity; they exert their effects by acting directly on dopamine receptors and imitate 
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the endogenous transmitter. Originally, they were launched, as an adjunct to levodopa treatment in patients 
displaying fluctuating motor reaction and dyskinesia’s associated with long-term use. Eventually, it has 
been proposed that the treatment should be introduced with a merger of low dose Levodopa and a dopamine 
agonist.  MAO-B inhibitors were extensively employed for their proven efficiency in symptom recovery 
and assumed ‘neuroprotective’ influence. Entacapone among other peripheral COMT inhibitors is often 
given with levodopa/ADDC-inhibitor therapy, they inhibit peripheral and thus increase yield of dopamine 
in the neurons (Leyva-Gómez et al., 2015).The elementary PD indications arise from seriously diminished 
action of dopaminergic neurons due to apoptosis in the substantia nigra, specifically on pars compacta.  
There are five significant pathways whose names are indicative of each projection area of the brain (Mariani 
et al., 2005). They join other brain regions with the basal ganglia, namely, motor, oculomotor, associative, 
limbic and orbitofrontal circuits. The syndrome symptoms manifest due to the influence exerted by the 
disruption routes which largely carter for motion, attention and learning. Of all routes, the motor route 
experiences the most significant effects. The PD symptomatic regimen employed (Table 1), conversely 
may inessentially trigger action of dopamine, permitting for motion routines to respond at 
unseemly intervals and thus bearing dyskinesia’s (Benitez-temino et al. 2008; Mariani et al., 2005)  
  
  
  
(Table 1), conversely may inessentially trigger action of dopamine, permitting for motion routines to 
respond at unseemly intervals and thus bearing dyskinesia’s.  
    
  
Name of drugs  
  
Target Protein  
Lipophilicity  
(Predicted)  
Log P  
  
BBB   
Permeability  
  
Side effects  
Pramipexole  
  
Selective dopamine receptor 
agonist  
2.18  1.86     No  Headache, Nausea and 
vomiting, gambling, 
hyper sexuality,  
overeating.  
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Ropinirole  
  
Suspected to be stimulation of 
postsynaptic dopamine D2-type 
receptors  
2.3  2.7     Yes  dyskinesia, nausea, 
dizziness, somnolence, 
hallucinations, and  
orthostatic hypotension  
  
Rotigotine  
D2 dopamine Receptor Agonist  3.69  4.7      Yes  Vomiting,  loss 
 of  
appetite, diarrhea  
Apomorphine  
  
Non-selective  dopamine  
agonist which activates D2 and  
D1 agonists.  
2.57  3.1       Yes   Powerful emetic, its  
adverse effects limit its 
use.  
Piribedile  
  
Dopamine receptor agonist  2.88  1.8         Yes  Nausea and vomiting, 
flatulence, dizziness or 
confusion  
Dihydro- 
ergocryptine  
  
Dopamine receptor 
agonist  
3.36  3.1  No  Nausea and Vomiting,  
Cardiac Arrhythmias,  
Postural hypotension  
Pergolide  
  
Dopamine receptor 
agonist  
3.03  4.2  Yes  Withdrawn 2003 due to risk 
of Cardiac fibrosis; sex 
addiction, gambling 
addiction  
Dopamine  Dopamine receptor 
agonist  
1.08  -0.7  No  Bradycardia, Nausea,  
Vomiting  
 
82  
  
Opicarpone  
  
COMT Inhibitor  0.99  2.1  No  Dyskinesia, Dizziness, Dry 
mouth, Constipation  
Tolcapone  
  
Inhibits Catechol 
Omethyltransferase  
COMT Inhibitor  
0.93  3.3  No  Lethal Liver insufficiency  
Carbidopa  
  
DOPA  
decarboxylase 
inhibitor  
0.47  -2.2  No  DOPA decarboxylase  
inhibitor  
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Amantadine  Increases dopamine release and          
 Blocks dopamine re-uptake  2.18  2.44  Yes  Irritability, Ataxia  
Selegiline  
  
Irreversible 
inhibition of  
MAO-B  
2.7  2.8  Yes  Mouth  sores,  
Exacerbates  L-dopa  
related dyskinesia’s  
Rasagilin
e  
  
Irreversible 
inhibition of  
MAO-B  
2.51  1.8  No  Mild  skin  rash,  
dizziness, vomiting,  
Lazabemi
de  
Irreversible 
inhibition of  
MAO-B  
1.07  0.2  No  Joint  pain,  mild  
headache, hair loss.  
Carbagoli
ne  
  
Dopamine 
 Rec
eptor  
Agonists  
2.6  3.4  Yes  Nervousness, stomach  
pain  
  
Cycrimin
e  
Anticholiner
gic- blocks 
acetyl 
Choline in 
central and 
peripheral 
nervous 
system  
3.58  
 
Yes  Lethargy,  psychosis, orthostatic 
 dizziness, blurred vision.  
Benserazi
de  
DOPA 
 Dec
arboxylase  
Inhibitor 
(DDC)  
0.72  -1.3  No  Nausea and Vomiting  
paranoia  and  
depression  
Benzatrop
ine  
Anticholiner
gic  
3.56  4.5  Yes  Blurred  vision,  
Cognitive changes,  
Dry Mouth  
Tropatepi
ne  
  
Anticholiner
gic  
3.55  4.8  Yes  Glaucoma  
Chlorphe
noxamine  
Anticholiner
gic  
4.1  3.73  Yes  Constipation, decreased coordination  
3.9  
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Budipine  NMDA receptor antagonist 
promotes the synthesis of  
dopamine.  
3.61  5.2  
  
Yes  Dizziness, dry mouth and  
loss of appetite.  
  
  
Permeating the blood–brain barrier; Hindering PD therapy  
A particular challenge in the pharmacologic remedies of neurodegenerative diseases, such as PD, is that of 
neurodegenerative conditions is trouble in crossing the BBB (Figure 2) and relaying a sufficient dose to the 
brain without metabolism (Silindir Gunay et al., 2016). Such challenges emanate from the protective 
blockades immediate to the brain such as the BBB and the blood-cerebrospinal fluid, which restrict transport 
of compounds and necessitate the creation and employment of novel methods. This is because there is a 
limited amount of regimens that can infiltrate due to lipophilic membranes and junctions embedding the 
barriers; namely the blood–brain (BBB) and placental (Devnarain et al., 2017).   
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Figure 2: Anti-Parkinson’s drugs that can pass the blood-brain-barrier, versus drugs that cannot.  
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Systemic interventions to unstitch the obstacle in the treatment of PD  
To overcome this setback in the treatment of PD, the drugs have to be transported across the BBB to elicit 
their full potential.  This could be attained through drug delivery systems where pre-BBB impermeable 
drugs are “carried” or modified to permeate the BB. Two strategies: (1) ameliorate the inhibitor and (2) 
convey the cargo to enhance the delivery of PD drugs across the BBB is further elaborated in this review 
(Figure 3).    
  
  
Figure 3: Graphical representation of interventions to unstitch the obstacle in the treatment of PD.  
  
  
  
  
Revamping inhibitors  
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 In this procedure, computational apparatus may be utilized to image and hone likely compounds, followed 
by compound manufacture and organic trials. These have been categorized into three phases; Phase I, II and 
III  
  
Phase I entails targeted collection of possible anti-Parkinson’s compounds. This encompasses screening for 
likely compounds with distinct physicochemical properties and anti-Parkinson’s action operating chemical 
databases, including adoption of absorption, distribution, metabolism, excretion (ADME) indicator devices 
namely, Swiss ADME and quantitative structure Structure-Activity relationship (QSAR) models, for the 
sake of altering out compounds that possess the qualities of traversing the BBB while maintaining or 
improving anti-PD efficacy (Oksel and Wang, 2013). The capacity of an active ingredient to penetrate the 
BBB is determined by its extent of lipophilicity, the molecular properties of unstable and hydrophobic side-
chains of the compound including molecular mass (Egido et al., 2015) .The focal lipophilic attributes that 
should be pondered incorporate the Hansch constant (p), hydrophobic fragmental constant (f), log P, 
capacity factor numbers from RPHPLC (log kw), processed log P values (CLOGP) and molecular lipophilic 
potential (MLP)(Oksel and Wang, 2013). Pertaining to the charge of the structure, only stable molecules 
can permeate the membrane to undergo re-protonation when it passes the membrane and enters the brain 
fluid (Egido et al., 2015). With increasing size of a compound, its aptitude to pervade the BBB dwindles 
(Arnott and Planey, 2012) .   
  
Phase II includes the forecast of lipid penetrability of the probable anti-PD compounds utilizing molecular 
dynamic imitations and Swiss ADME (3D modeled lipid simulations). Owing to the encircling lipid film of 
the BBB, it is essential to evaluate compound interfaces with the focal enzyme inside the lipid film 
(Rodriguez-espigares et al., 2014).    
  
Phase III includes the computation of binding affinities between probable anti-Parkinson’s substrates, 
which traverse the BBB, and areas of the brain affected by PD through binding free computations and 
molecular docking of specific compounds into the target receptor (Meng et al., 2011).  
  
Subsequent to the course imagery, compound synthesis is a prerogative for additional examination. The 
development of the carbon structure and the removal/addition/transformation of side-chains are carried out 
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for the formation of a compound product. Ligand-binding tests are then done to verify the compound quality, 
the do target enzyme are mixed with compound of concern into diluent (e.g. water) to permit the compound 
to engage with the active site moieties of the enzyme (Hulme et al., 2010). Binding inquiries yield 
dependable analysis of binding affinities, errors and binding method (Hulme et al., 2010). Additional 
research involving biological examination will explore toxicity and efficacy of a compound, encompassing 
in vitro studies (cellular level), in vivo studies (organism level) and eventually clinical tests. Microscale 
thermophoresis (MST) might be employed for the sake of scrutinizing the interplay between the substrates 
and receptors, analytically, based on the regulated motion of particles across a slope of the temperature (Ali 
et al., 2012; Scheuermann et al., 2016) .  
  
Research on treatment of Parkinson’s disease has made some tremendous steps in exploring symptomatic 
treatment by graduating from the day a limited dopamine which could not pass the BBB to the discovery of 
ground breaking pro-drug Levodopa and the use accompaniment of enzyme inhibitors e.g. Carbidopa– 
Levodopa the most effective and well-tolerated pharmacological remedies on offer to patients, used for the 
treatment of rigidity and rest tremor (Brichta et al., 2013). Regardless of the various developments in 
approaches for treatment of this neurodegenerative disorder there are still challenges that restrain effective 
therapy, namely the shipment of drugs through the BBB to the target brain tissue and side effects noticed 
during long-term treatment. The use of drug delivery systems such as nanoparticles for more optimized 
therapy is being explored for PD therapy and is expected to help diminish adverse effects.  
  
“Drug Carts or A Medicinal Conveyor”  
The controlled drug release technology has evolved immensely over the last six decades (Figure 1). It 
commenced in 1952 with the introduction of the first sustained release preparation. Figure shows how. 
There is sundry PD research avenues that are prospective ground for future mediations including therapeutic 
centered either partly or completely, on Nano-polymer preparations. We are still face with the problems of 
“on-off” episodes, namely, dyskinesia’s and poor drug solubility. Complementary to engineering new BBB-
permeable medicines, the use of drug carriers have been effective in transporting medicines to the brain. 
This method removes the extra time and expenses necessitated to craft and formulate fresh medicines and 
drug carriers. A drug delivery system could be employed to transport a  
BBB-impermeable drug to the brain and permit for the drug to execute its function against PD symptoms 
(Newland et al., 2015).  
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Throughout the development medicines of different routes in different certain benefits accompanied by 
challenges have been noticed and areas to be harnessed and a cause of concern respectively. Figure 4 
highlights some of the characteristics to be noted in individual polymers while preparing various 
formulations to treat PD. The foremost prerogative for addressing the bioavailability and stability restraints 
of poorly soluble drugs is the diminution of particle size to nanoscale for improved solubility and drug 
targeting (Gigliobianco et al., 2018).  
  
  
Figure 4: depiction of the major characteristics of nanocrystals (Prepared by author).  
  
The drugs listed in (Table2) have been confirmed to deal with motor or non-motor symptoms of PD in 
secluded in-vitro testing. These include drugs such as dihydroegocryptine and pramipexole, however the 
drugs are unable to route through the BBB to thwart PD symptoms (Table 5.1). Traversing the blood BBB 
remains a major hindrance in development of efficient PD treatments and without a drug delivery system 
these molecules stay on the peripheral side of the BBB like cargo without a carrier and remain useless to 
the dopamine-starved brain cells.   
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Table 2: Properties exhibited by potential Parkinson’s drug carriers  
  
Drug carrier  Drug Summary  
Chitosan   Has shown to effectively transport Carbagoline effectively and accumulate 
high concentrations in brain through evoking paracellular drug transport  
(Sharma et al., 2009).  
Poly  (ethylene  glycol)-
poly (colic-co-glycolic-acid) 
 (PEG-PLGA)  
PEG-PLGA are biodegradable with efficient transport of rotigotine across 
BBB for PD treatment (Wang et al., 2001).   
Poly (butyl cyanoacrylate)  PBCA coated with polysorbate 80 enhances the efficiency of nerve growth 
factor and is shown to reverse MPTP induced PD in rats. (Kurakhmaeva et 
al., 2009)  
Chitosan  In-vitro tests have affirmed that dopamine-loaded chitosan has diminished 
cytotoxicity of free dopamine. (Trapani et al., 2011)  
PLGA  Levodopa nanoparticle encase benserazide PLGA microspheres favorably 
removed duskiness in rat. (Choudhury et al., 2017)    
Dextran  Manageable  equilibrium  of  expansion,  mechanical 
 tenacity  and  
degradability.(Hovgaard and Brndsted, 1995)  
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Odorranalectin  (OL)  PEG- 
PLGA conjugated nanoparticles  
  The outcome implied that    OL boosted the brain delivery of NPs.   
(Wen et al., 2011)    
Polyvinyl alcohol (PVA)  Is impervious to grease oils, and solvents. It has a lofty tensile strength and 
elasticity, as well as steep oxygen and aroma blockade attributes 
 (Fromageau 
 
  
 et al., 2003).  
PVP  It escalates the water solubility of hydrophobic substances. In normal doses 
naturally passes through the body with little to no harm when taken orally  
(Fromageau et al., 2003; Yoshida et al., 2008).  
Pluronics  This sol- gel transition is can also be sensitive to concentration and 
temperature, is also affected by salts and alcohols by their influence on 
polymer hydration (Feilden et al., 2016).  
HPMC  Given with Nifedipine in trial on rabbit specimen improved deficient 
solubility and dissolution speed of efficacious Ca antagonist(Yoshida et al.,  
2008; Ghosal et al., 2011).  
Eudagrit (L and S)  The polymer only dissolves between a PH of 6 and 7, which enables it to 
resist the first-pass reactions in the stomach and liver which could potentially 
metabolize the loaded drug (Krögel and Bodmeier, 1999).  
Ethocel  Ethyl cellulose materials are flexible, organosoluble, and thermoplastic 
polymers. Its pharmaceutically approved products cover the taste of sour 
medicines, improve the strength and empower controlled release mixtures  
(Decuzzi et al., 2009).  
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Discussion  
 It is beyond any doubt that the computational tool kit is capable fulfilling the ordeal of identifying present 
properties, making required for current FDA approved drugs and giving reliable insight on the possibility 
of using the listed anti-Parkinson’s drugs to eradicate or by the least manage the onslaught being perpetuated 
by PD globally. There is ongoing search on the cure and symptomatic treatment of PD and a significant 
foremost challenge lies with delivery across the BBB, side effects and low solubility of drugs. The 
approaches eluded in this review serve to deliver intelligence on additional studies on the design of drugs 
with improved BBB permeability profile for better curative and symptomatic treatment results, and less side 
effects for better patient adherence to medication.   
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                                                   CHAPTER 6  
Overall Conclusions and Recommendations for Future Studies  
This Chapter provide a general conclusion, highlights the significance of the findings in the study and 
outlines recommendations for the future  
6.1. General conclusion   
Since Parkinson’s is envisioned to upset more lives in correspondence with a staggering increase in elderly 
population. There are growing conversations neurodegenerative tide of PD also poses non-motor symptoms 
and some of them are: autonomic dysfunctions, apathy, depressions, sleep disorders, fatigue, pain and 
dementia great deal of research pertaining to the treatment will be of necessity. The growth Insilico studies 
of polymer-drug structure and interaction is expected to bring about significant breakthrough to the research 
and medical arena in a year to come.  
One of the major challenges that we encountered was with the establishing whether this improvement in 
this rate regulating solubility will result with in an intensification in bioavailability in in-vivo as in the invitro 
test. Therefore, the residual challenges in cementing the outcomes of both experimental and computational 
studies done on the interaction between polymeric nanoparticles and domperidone would be to establish the 
efficiency of the antiemetic drug in an animal specimen. Fortunately, the use of animals in testing for 
neurodegenerative diseases has become more conventional over the years. What also remains   It is 
estimated that 90% of new drugs in the development pipeline can be classified as poorly soluble (Dennison 
2016).   
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Given the great number of poorly soluble drugs, novel and appropriate formulations as well as technological 
solutions are needed to sufficiently increase drug bioavailability, accordingly to the administration route 
(Gigliobianco, Casadidio, Censi & Di Martino 2018) To date, the classical method for enhancing the 
dissolution rate of poorly soluble drugs is to reduce particle size, in particula through micronization 
(Gigliobianco et al., 2018). However, it seems that further improvement in the drug dissolution rate and 
thus in bioavailability demands a shifting from micronization to nanonization. This requires various and 
innovative technological methods, as well as novel resolutions to overcome all of the physicochemical and 
stability problems linked with nanostructures.  
  
Credits to the advanced process technologies and analytical methods harnessed in the last  
decades, a considerable number of pharmaceutical nanocrystal formulations are now on the market and 
several are under development (Gigliobianco et a.l., 2018). Nanocrystals consisting of pure drugs and a 
minimum of surface   
  
Molecular modeling and computational pharmaceutics methods have been broadly adopted in drug 
discovery fields. A wide range of tools are being used to model or mimic the behavior of molecules and 
assist investigate formulation at the molecular level. Computational pharmaceutics enables us to understand 
and develop new pharmaceutical drug delivery systems. Regardless of plenty investigations on this field of 
research, restricted has been accounts on the oral therapy of this anti-Parkinson’s drug, the gap in molecular 
modelling applications on antimicrobial drug delivery systems. Another disparity in the literature is the 
research that specifically aimed to explore the interactions between the nanoparticles and biological targets 
(proteins/enzymes), one critical example being the interactions of domperidone with receptor nano-
polymers (Sliwoski, Kothiwale, Meiler & Lowe 2014).   
 6.2. Significance of the findings in the study  
The computational approaches and tools applied in this work and the combined experimentadata have 
successfully provided molecular insight into the design, structural, conformational and interaction features 
of the nano-drug delivery systems investigated in this thesis. Considering the aim, objectives and outcomes, 
the significance of the findings includes the following:  
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Recent pharmaceutical products:  
The novel DOMP-nanopolymeric particles successfully designed and characterized by molecular modelling 
tools in this study can stimulate local pharmaceutical industries to manufacture cost-effective superior 
medicines (Ullah, Khan, Ahmed, Govender, Faidah, de Matas, Shahid, Minhas, Sohail & Khurram 2018).  
Invention of new knowledge to the scientific community  
The various studies and findings of the study have contributed to the pharmaceutical sciences knowledge 
database in several ways. These include the following:  
• New knowledge was obtained through the in-silico studies that were performed to understand 
the possible interactions of DOMP and the different polymer molecules, investigate molecular 
mechanism behind the enhanced entrapment of domperidone, and determine the stability, structural 
and conformational features of these polymeric nanoparticles.  
• In the case of the DOMP-nanopolymeric studies, new knowledge was obtained in that this is the 
first account of investigating the potential uses of DOMP-nanopolymers as potential oral 
antiParkinson’s formulations using hybrid molecular modelling and experimental endorsements 
(Ullah 2018).   
  
6.3. Recommendations for future studies  
Although a wide range of molecular modelling approaches were applied in this work and successfully 
demonstrated the applications of various tools to understand and characterize the  
structural and dynamic aspects of different drug delivery systems including, DOMP-nanoparticles, further 
research is expedient to enhance and drive toward the design of future superior formulations. The following 
recommendations could be considered in future studies:  
• In the case of DOMP, the use of wide range of drug nano-carriers various polymers, need to be 
explored for potential antibacterial activities. The applications of molecular modelling tools would 
serve as a powerful tool, as hundreds of drug-nanoparticles could be investigated using in silico 
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methods before performing experimental investigations. This could reduce the time and cost 
associated with experimental screening hundreds of molecules using wet lab  
  
• More computational research could be done on the structure of domperidone, in relation with its 
biological interaction and consequent side-effects; and its physicochemical qualities and 
consequent low solubility and dissolution. This insight into quantitative structure activity 
relationship (QSAR) could open doors to more efficient therapy in PD and ND and conditions.  
  
Finally, the general findings of this research therefore demonstrate the potential applications of the diverse 
molecular modelling approach in understanding, distinguishing and designing novel nano-based drug 
delivery systems in anti-Parkinson’s therapy. This research has made consequential contributions to the 
field of Nano-based strategic mediations to deal with the challenges associated with BSC II and BSC IV 
drugs (Tsume, Mudie, Langguth & Amidon 2014). The realization of nanotechnology to address the present 
crisis in therapy of global neurodegenerative drug will be dependent on future exhaustive and 
multidisciplinary analysis.  
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Abstract 
The aim of this study was to employ experimental and molecular modelling approaches to use molecular level interactions 
to rationalise the selection of suitable polymers for use in the production of stable domperidone (DOMP) nanocrystals with 
enhanced bioavailability. A low-energy antisolvent precipitation method was used for the preparation and screening of 
polymers for stable nanocrystals of DOMP. Ethyl cellulose was found to be very efficient in producing stable DOMP 
nanocrystals with particle size of 130 ± 3 nm. Moreover, the combination of hydroxypropyl methylcellulose and polyvinyl 
alcohol was also shown to be better in producing DOMP nanocrystals with smaller particle size (200 ± 3.5 nm). DOMP 
nanosuspension stored at 2–8 °C and at room temperature (25 °C) exhibited better stability compared to the samples 
stored at 40 °C. Crystallinity of the unprocessed and processed DOMP was monitored by differential scanning calorimetry 
and powder X-ray diffraction. DOMP nanocrystals gave enhanced dissolution rate compared to the unprocessed drug 
substance. DOMP nanocrystals at a dose of 10 mg/kg in rats showed enhanced bioavailability compared to the raw drug 
substance and marketed formulation. A significant increase in plasma concentration of 2.6 μg/mL with a significant 
decrease in time (1 h) to reach maximum plasma concentration was observed for DOMP nanocrystals compared to the raw 
DOMP. Molecular modelling studies provided underpinning knowledge at the molecular level of the DOMP-polymer 
nanocrystal interactions and substantiated the experimental studies. This included an understanding of the impact of 
polymers on the size of nanocrystals and their associated stability characteristics. 
Keywords Domperidone . Nanocrystals . Molecular modelling . Polymers . Dissolution . Enhancedbioavailability 
Introduction 
The oral route of administration is one of the most convenient, 
useful and frequently used means to administer drugs [1]. In 
this regard, however, the poor aqueous solubility of drugs 
has been the leading factor, limiting the attractiveness of 
this route for some compounds and leading to low oral 
bioavailability and dissolution rate via this route. For drugs 
classified as class 
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II according to the Biopharmaceutics Classification System 
(BCS), solubility and dissolution rate are of great 
importance and considered as the basic factors, which 
influence the rate and extent of drug absorption from the 
gastrointestinal tract (GIT) [2]. According to recent 
publications, approximately 40% of compounds in 
development are subject to poor water solubility [3]. To 
reach the therapeutic plasma concentrations, poorly water-
soluble drugs are often given at high doses. With the 
variability in exposure, which is often observed for drugs of 
this nature, this provides risks of suboptimal efficacy and 
safety, particularly for drugswith low therapeutic index. 
Inthis regard, from a clinical perspective, it is more 
desirable to use low doses of drugs having greater 
dissolution rate, better absorption and enhanced 
bioavailability. A number of wellestablished strategies exist 
for enhancing the solubility and dissolution rates of drugs 
with low aqueous solubility [4, 5]. 
In the current pharmaceutical drug delivery research 
domain, nanotechnology is an emerging field, where drugs 
with sub-micron particle size are increasingly being 
considered as a means to address the problem of poor 
aqueous solubility. Owing to their significantly high surface 
area to volume ratio, the nanoparticles [6, 7] are believed 
to provide an excellent means to drive dissolution in the GI 
tract. The Noyes– Whitney equation gives a sound basis for 
this dissolution rate enhancement with reduction of the 
particle size to the nanosized range, enhancing the surface 
free energy and surface area leading to increases in water 
solubility and rate of dissolution [8]. 
In terms of methods of producing nanoparticulate drugs, 
two major techniques have been described, which include 
bottom-up and top-down methods. The typical top-down 
methodsincludewetmilling andhigh pressure 
homogenisation [9], whereas the bottom-up methods are 
mainly based on the principle of antisolvent crystallisation 
[10]. Nanosuspensions are the preparations composed of 
suspended particles in nanoform, stabilisedby polymers 
and surfactants. The patented solvent displacement 
method was first used by Fessi et al. for the preparation of 
nanosuspensions [11]. 
Domperidone is a pharmacological antagonist of 
dopamine-2 receptor and belongs to class II of the BCS (Fig. 
1). Domperidone (DOMP) is used as antiemetic as well 
 
as prokinetic representative by producing its effect on the 
chemoreceptor trigger zone and also motor function of the 
small intestine and stomach. This drug has poor aqueous 
solubility (0.986 mg/L), while oral bio-availability is 12 to 18 
% during fasting and 24% after food [12]. The poor water 
solubility seems to be one of the probable causes for its low 
bioavailability [13]. The conversion of DOMP into stable 
nanocrystals could potentially be one of the promising 
solutions to address this issue. 
This study focussed on the production of stable 
nanocrystals of DOMP and investigated using molecular 
dynamics simulation studies the polymer-drug nanocrystal 
interactions underpinning the use of the low-energy 
antisolvent precipitation for nanocrystal manufacture. A 
number of studies have reported the impact of polymers on 
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N 
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Fig. 1 Chemical structure of domperidone  
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particle sizes of drug nanoparticles. Despite these learnings, 
the molecular level interactions of polymers and drug 
nanocrystals are still an interesting issue yet to be fully 
resolved [14]. In this study, extensive molecular modelling 
was coupled with the experimental results to investigate 
and evaluate the correlation between molecular 
interactions and drug and stabilisers and nanoparticle 
properties. The traditional experiments cannot provide the 
molecular insight of the nanocrystal-polymer interactions 
in isolation [15, 16]. The comprehensive molecular level 
understanding gained from this study will be useful going 
forward for nanoformulation scientists to optimise polymer 
selection for stable nanocrystal production for a range of 
different APIs. 
Materials and methods 
Materials 
DOMP was gifted by Stanley Pharma having batch no. 
BDOM/1302036 (Vasodha Pharma Chem Lab 78/A Vengal 
Rao Nagar Hyderabad-38 Andhra Pradesh, India), and 
ethanol, n-hexane, polyvinyl pyrrolidone (PVP) (CAS 
number: 9003-39-8) and hydroxypropyl methylcellulose ( 
HPMC ) (9004-65-3, USA) were also gifted by Stanley 
Pharma. Sprague-Dawley rats (150–200 g) were used for 
bioavailability studies. 
Preparation of DOMP nanosuspension 
A low-energy antisolvent precipitation method was 
employed for the production of stable nanocrystals of 
DOMP [14]. The 
DOMP solution (10 mg/mL) was prepared in 
dimethylformamide (DMF) and then filled into the syringe, 
and with the help of a syringe pump, the solution was 
quickly injected at a constant flow rate of 2–8 mL/min into 
the polymer solutions that served as antisolvent phase, 
with continuous stirring rate at 600–1000 rpm. Different 
polymers and subsequent t combinations thereof were 
used to evaluate their impact on produced nanocrystals of 
DOMP. The polymer solutions were composed of 1% (w/v) 
of each of the polymers which included PVP, ethyl cellulose, 
HPMC, PVA, Pluronic F127 and Eudragit (EUD). Ethocel was 
dissolved in drug solutions in DMF and then injected into 
the water. The produced DOMP nanocrystals were filtered 
and vacuum dried. 
Physicochemical characterisation 
Particle size measurements 
Particle size and associated polydispersity index (PI) 
measurements of the produced nanoparticles of DOMP 
were carried out in triplicate using dynamic light scattering 
(Zetasizer® NanoS, Malvern Instruments, UK), which 
measures the hydrodynamic diameter including the 
solvation layer around each particle. 
Morphological studies 
Scanning electron microscopy The principle used in the 
operation of scanning electron microscopy (SEM) is light 
reflection microscopy. Reflection of electrons occurs as a 
result of incident light striking the surface of the powder 
sample and colliding with particle surfaces. The reflected 
electrons are picked up by the detector and are then 
transformed into an image by algorithm. Scanning electron 
microscopy is applied for the description of surface 
morphology of the powder sample and provides good 
resolution down to scale of several nanometers. 
Surface morphology studies of the unprocessed DOMP 
were carried out by placing the sample on a grid covered 
with gold sputter coater (SPI, USA) using Jeol JSM5910 
scanning electron microscope at an operating voltage of 30 
mA for a duration of 2 min and an accelerating voltage of 
20 kV. 
Transmission electron microscopy The size and appearance 
of the produced DOMP nanoparticles were evaluated using 
transmission electron microscopy (TEM) ( TEM-1200Ex; 
Japan Electron Optics Laboratory Corporation, Tokyo, 
Japan). The images of DOMP nanoparticles were taken at 
120 kV. The drops of DOMP nanosuspensions were 
deposited on 200 mesh copper grid followed by coating 
with formvar/ carbon (code no: S162) and drying at room 
temperature. Owing to the low conductivity of the 
produced samples, they were negatively stained using 2% 
solution of magnesium uranyl acetate. 
Differential scanning calorimetry 
To investigate and evaluate the impact of particle size on 
the thermal profile of the produced DOMP nanoparticles, 
the comparative differential scanning calorimetry (DSC) 
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studies were carried out. The samples were scanned using 
the Mettler Toledo Differential Scanning Calorimeter ( 
MettlerToledo®, USA). Samples (2–3 mg) of unprocessed 
and processed DOMP were weighed into separate 
aluminium pans, which were sealed and then analysed by 
heating from 30 to 300 °C at a heating rate of 10 °C min−1 
and nitrogen flow of 40 mL/min. Indium was used as a 
standard for calibration of the instrument. 
Powder X-ray diffraction studies 
The prepared nanoparticles and unprocessed drug 
substance were subjected to testing for crystallinity using 
PXRD powder X-ray diffractometer (D8 ADVANCE, Bruker, 
Germany). The silicon-well sample holder was used for the 
analysis of nanoparticle samples, while the plastic sample 
holder was used for the raw drug substance. The 
nanoparticle sample and raw drug substance were scanned 
in triplicate in the range 0° ≤ 2θ≤ 70° using copper Kα as the 
radiation source with 1 mm slit at 1.542 Å wavelength. Step 
size was 0.05° and the time lapse between the steps was 2 
s. 
Stability studies 
The stability of nanoparticles, particularly those produced 
by the bottom-up method, is very important, especially 
because agglomeration and particle growth can occur 
quickly, leading to the loss of rapid dissolution 
performance. In this study, the produced DOMP 
nanosuspensions were subjected to testing of physical 
stability over a duration of 90 days following storage at 2–
8, 25 and 40 °C. This study was designed to monitor the rate 
and extent of particle growth with measurements of 
particle size being made using dynamic light scattering. 
Computational methods 
Molecular docking of polymers and DOMP 
A short MD run was performed on the polymers to obtain 
relaxed energy conformers prior to docking. The Molecular 
docking software utilised included Raccoon [17], Autodock 
Graphical user interface supplied by MGL tools [18] and 
AutoDockVina [19] with default docking parameters. Prior 
to docking, Gasteiger charges [20] were added to polymers 
as well as domperidone and the non-polar hydrogen atoms 
were merged to carbon atoms. The grid box was set to 
cover the entire polymer to allow for the best-docked pose. 
The optimal geometric conformation bearing the best 
binding energy was picked from the View Dock feature on 
Chimera [21] and the complex saved with the reference 
polymers. The polymer-domperidone for each system was 
prepared using Chimera and MMV molecular modelling 
suites [22] and later subjected to molecular dynamic 
simulations. 
Molecular dynamic simulations 
GPU version of the PMEMD engine in Amber14 software 
package was utilised to execute unrestrained all-atom MD 
simulations. The Restrained Electrostatic Potential ( RESP ) 
and the General AMBER Force Field (GAFF) [23] systems 
were used by ANTECHAMBER [24] to generate the atomic 
partial charges for the polymers and domperidone. The 
systems were solvated in a cubic box of TIP3P water, such 
that all atoms were within 10 Å of a box edge. Long-range 
electrostatic interactions were treated with the Ewald 
method and a van der Waals cut-off of 12 Å. Each of the 
systems was minimised for 1000 steps (500 steepest 
descent followed by 2500 steps of the conjugate gradient). 
The langevin thermostat, with a collision frequency of 1.0 
ps−1 with a harmonic restraint of 5 kcal/mol on the solutes, 
was applied during the gradual heating of the systems to a 
temperature of 300 K in the canonical ensemble for 50 ps. 
This was followed by 50 ps of density equilibration in the 
NPT ensemble and a final 500-ps equilibration at 300 K, 1 
bar pressure and a coupling constant of 2 ps, and then by a 
MD production run of 50 ns. System coordinates were then 
saved every 1 ps and analysed using the PTRAJ module 
employed in AMBER14 [25]. The root mean square 
deviation (RMSD) was employed to establish the stability of 
the 12 systems over the 50-ns trajectory. 
Binding free energy calculation 
Calculations of free binding energies were engaged using 
the molecular mechanics/GB surface area method 
(MM/GBSA) [26]. This was carried out to evaluate the 
binding affinities of each system. Binding free energies 
were then averaged over 5000 snapshots extracted from 
the 50-ns trajectory. Figure 2 depicts free binding energy 
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(ΔG), which was computed by the MM/GBSA method for 
each molecular species (complex, ligand and polymer). 
Bioavailability studies 
The pharmacokinetics studies of unprocessed 
domperidone, its fabricated nanocrystals (DOMP-nano), 
prepared solid dosage form (DOMP-nano dosage form) and 
marketed formulations were carried out using rats as the 
animal model.SpragueDawley rats (150–200 g) were 
administered with an oral dose of 10 mg/kg of 
domperidone, its nanoparticles, its nanodosage form and 
marketed drug, and blood was collected after 0.25, 0.5, 1, 
2, 3, 4, 6, 8, 10 and 12 h post-administration (n = 6 rats each 
for different time periods). The collected blood samples 
were centrifuged and plasma was obtained. The blood 
plasma was quantified for DOMP using a reported HPLC 
method [27]. The pharmacokinetics parameters in the 
plasma were determined using the pharmacokinetic 
software WinNonLin (v 4.0; Pharsight Software, Mountain 
View, CA, USA). The pharmacokinetics parameters 
determined include maximal plasma concentration (Cmax), 
time to reach maximal plasma concentration (Tmax), half-life 
(t1/2) and the area under the concentration-time curve ( 
AUC ). 
Dissolution studies 
Dissolution studies on pure DOMP as well as the 
nanoparticles prepared through EPN were performed using 
two separate dissolution tests, both using the U.S. 
Pharmacopoeia (USP) tablet dissolution test apparatus 2 
(six stations) with the paddle rotating at 50 rpm in 900 mL 
of both pH 1.2 (0.1 N HCl) media and in a separate test 6.8 
pH phosphate buffer at 37 ± 0.5 °C. All drugs equivalent to 
10 mg of DOMP were used as samples for the dissolution 
test. At 10, 30 and 60 min intervals, 5 mL samples were 
withdrawn, filtered through a syringe filter (0.02μm) and 
assayed for DOMP content by measuring the absorbance at 
284 nm using a UVvisible spectrophotometer (Shimadzu 
UV-1700). Fresh medium (5 mL), pre-warmed at 37 ± 0.5 °C, 
was added to the dissolution medium after each sampling 
to maintain a constant volume throughout the test. 
Dissolution studies were performed in triplicate (n = 3) [15]. 
Statistical analysis 
All the tests were run in triplicate and the results were given 
as mean ± standard mean error (SEM). Mean values were 
compared using ANOVA test and differences were 
considered statistically significant at the level of P < 0.05 
using Statistics 8.1 software. 
Results and discussion 
Preparation of DOMP nanosuspension using 
antisolvent precipitation method 
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Nanosuspensions of DOMP were produced by antisolvent 
precipitation. The particle sizes of nanosuspensions 
produced using this method are given in Table 1. Different 
polymer solutions were used as antisolvent phase with 
different combinations of polymers to investigate the 
impact of the polymers on particle sizes of the produced 
DOMP nanocrystals. It was observed that Ethocel was the 
most suitable single polymer to produce DOMP 
nanocrystals with small particle size 130.0 ± 3.0 (Table 1 
and Fig. 3). This shows that Ethocel strongly adsorbed onto 
the surface of DOMP nanocrystals to establish the steric 
stabilisation with subsequent small particle size and low PDI 
value. In addition, HPMC was also found comparatively 
effective as a single polymer to control the size of DOMP 
nanocrystals (300 ± 4.0) (Table 1). However, when HPMC 
was combined with PVA in the antisolvent phase, the 
impact became more predominant in terms of controlling 
the particle size. The combination of HPMC-PVA produced 
DOMP nanocrystals with particle size 200 ± 3.5. DOMP 
nanoparticles produced at optimised conditions were 
quickly recovered by vacuum evaporation of all solvent and 
antisolvent using a rotary evaporator and were then 
washed and dried. The resulted PDI was below 0.5, which 
shows homogenous particle size distribution of the 
suspended particles [28, 29]. 
The highly concentrated drug solutions injected into the 
antisolvent phase can potentially produce high levels of 
supersaturation and, consequently, nanoparticles with 
small particle size. The SAS ratio is a veryimportant process 
parameter, which should be optimised during APSP 
production of nanoparticles, whereby the barrier for the 
existing species to be grown during mixing of the solvent 
antisolvent phases is affected by this parameter. In this 
study, it has been observed that DOMP nanoparticles with 
small particle size 130.00 ± 3.0 nm were produced using a 
high SAS ratio (Fig. 3) while using the antisolvent phase with 
Ethocel. At low SAS ratio, the available diffusion distance 
for the growing species is low and can potentially lead to 
high nucleation with subsequent comparatively large 
particle sizes being produced [30, 31]. 
Morphological examination 
The morphology studies of raw and processed DOMP were 
carried out by SEM and TEM, respectively. SEM observation 
showed some differences in size and shape of the 
unprocessed DOMP particles (Fig. 4a). The average particle 
size was found to be 10–15 μm and most of the particles 
 
Fig. 2 Diagrammatic representation of thermodynamic calculation (MM/GBSA) used in the study (prepared by the authors) 
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were shown to be cuboidal and prism-like. 
Some traces of oval shape particles 
Table 1 Impact of polymers on particle sizes and 
PDI values of DOMP nanosuspension 
DOMP-polymer complexes Particle size ± SD PDI ± SD 
Ethocel 130.0 ± 3.0 0.15 ± 
0.01 
Pluronic 1200 ± 7.5 0.85 ± 
0.06 
PVP 950.0 ± 5.0 0.77 ± 
0.05 
PVA 400.0 ± 4.5 0.50 ± 
0.03 
EUD 1175 ± 7.0 0.80 ± 
0.06 
HPMC 300 ± 4.0 0.40 ± 
0.02 
EUD-PVA 775 ± 6.0 0.65 ± 
0.04 
EUD-PVP 985 ± 5.7 0.80 ± 
0.05 
HPMC-PVA 200 ± 3.5 0.20 ± 
0.02 
HPMC-PVP 570.0 ± 5.0 0.52 ± 
0.03 
HPMC-EUD 550 ± 6.5 0.60 ± 
0.04 
PVA-PVP 650 ± 5.2 0.40 ± 
0.02 
were also observed, although all particles appeared to 
demonstrate regular crystalline morphologies (Fig. 4b). 
TEM images of the DOMP nanoparticles demonstrated that 
most of the particles were spherical in shape with some 
traces of the triangular shape particles. In addition, the TEM 
results exhibited that all the nanoparticles were 
homogeneously distributed with no clumps or aggregates. 
The particle size was shown to be approximately 100.0 nm 
in good agreement with DLS data. The minor difference in 
the particle size measured using DLS and TEM is related to 
the difference in the principles of the two techniques. In 
DLS, the electrical double layers surrounding the individual 
particle could are also measured, whereas TEM only 
measures the actual particles [29]. 
PXRD analysis 
Fig. 3 Particle size distribution of 
DOMP nanoparticles 
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PXRD analysis was carried out for raw and DOMP 
nanoparticles. PXRD diffractograms show that raw DOMP 
has sharp peaks of high intensity compared to DOMP 
nanoparticles (Fig. 5a). The nanoformulation gives lower 
intensity, broader peaks, which are typical of crystalline 
particles with low particle size peaks (Fig. 5b). X-ray 
diffractograms with lower peak intensities and the absence 
of some peaks have also been previously reported by other 
researchers for crystalline nanoparticles [32–34]. 
Furthermore, nanoparticles can result in broadening and 
disappearance of some peaks in X-ray diffractograms. 
Owing to small angular reflection by the  
 
Fig. 5 of the unprocessed ( PXRD patterns a ) and DOMP nanoparticles  
( b )  
Fig. 4 SEM image of raw DOMP ( a ) and TEM micrographs of processed 
DOMP   particles   ( b )   
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Fig. 6 DSC thermograms of the unprocessed DOMP and DOMP 
nanocrystals 
smaller particles, the peak intensity of X-ray diffractograms 
is reduced. For domperidone nanoparticles, the small 
sample sizes with fewer particles can also result in lower 
intensity reflections. 
DSC analysis 
DSCthermogramsofpureDOMPandthepreparednanocrystal
s 
areshowninFig.6.Thereappearedanintenseendothermicpe
ak 
atapproximately238°CfortheunprocessedDOMP.Itisknown 
that a crystalline structure will give a peak at the melting 
point temperature with high heat enthalpy (ΔH) values 
compared to that of amorphous structures of the same 
materials. The produced nanocrystals have low values of 
ΔH representing reduction in crystallinity of the resulted 
nanocrystals. The produced nanocrystals have shown a 
melting point peak at lower temperature compared to the 
unprocessed DOMP, which is typical of nanocrystalline 
materials. 
The endothermic peak of the processed DOMP was 
broadened, which is potentially caused by the packing 
density of the produced nanocrystals, incorporating traces 
of stabilising polymers [35]. 
Molecular docking and conformational analysis 
of polymer systems 
Molecular docking is a conventional method in 
computational chemistry, which is utilised in the prediction 
of optimised geometric conformations of a ligand within an 
appropriate binding site [36]. Of the docked polymer-
DOMP complexes (Figs. 7 and 8), the highest binding 
affinity was observed for the HPMC-EUD co-polymer (− 6.0 
kcal/mol). Of the monopolymer complexes, PVP 
demonstrated the highest binding affinity (− 5.2 kcal/mol). 
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Fig. 7 Binding affinity results from molecular docking of domperidone-monopolymer 
Drug Deliv. and Transl. Res.  
 
 
complexes Fig. 8 Binding affinity results from molecular docking of domperidone-copolymer 
complexes 
The molecular docking results, however, only take into 
account the geometric orientation of domperidone when 
bound to suitable regions of the polymers and, thus, may 
be inconclusive when identifying the forces that stabilise 
domperidone to the polymers. To overcome any binding 
mode ubiquities, molecular dynamics were carried out to 
simulate the interaction of domperidone with the polymers 
over a 50-ns trajectory. After allowing domperidone to 
equilibrate with the polymers, the binding mechanism and 
stabilising intramolecular forces were investigated using 
binding free energy calculations. 
Polymer system stability through molecular dynamic 
simulations 
The stability of trajectories was identified using RMSD over 
the 50-ns simulation, the potential energy of the polymer-
domperidone remained stable during the MD trajectories 
and convergence was reached at approximately 20 ns. 
Thermodynamic energy analysis 
The total binding free energy for each of the 12 
polymerdomperidone complexes was calculated using the 
MM/ GBSA approach to better understand the various 
energy contributions stabilising the polymer to 
domperidone and to assess which polymer-complex 
showed the most favourable intermolecular interactions. 
Based on Table 2, a conformational analysis was performed 
to distinguish between the most favourable polymer-
domperidone complexes. 
Calculating the thermodynamic energy between a 
polymer and a drug gives the approximate intensity and 
stability of interactions between the molecules; thus, a 
higher binding interaction will result in a more stable 
polymer-drug complex [37]. 
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Upon analysis of Table 2, the most favourable 
interactions were observed in the Ethocel system (− 27.26 
kcal/mol), while the Pluronic complex showed the least 
favourable binding free energy (− 1.20 kcal/mol). It was also 
interesting to note that the inclusion of EUD significantly 
lowered the thermodynamic energy of the co-polymer 
complexes, as the addition of EUD to PVA decreased the 
free binding energy by 9.38 kcal/mol. This 
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Table 2 Binding free energy analysis (kcal/mol) for polymer-domperidone complexes 
Complex Energy components ( kcal/mol )    
ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
Single-polymer systems      
Ethocel − 30.37 ± 0.24 − 6.95 ± 0.43 − 37.32 ± 0.43 10.06 ± 0.33 − 27.26 ± 
0.24 
Pluronic − 3.69 ± 0.05 0.29 ± 0.079 − 3.40 ± 0.96 2.19 ± 0.09 − 1.20 ± 
0.54 
PVP − 5.52 ± 2.68 − 20.94 ± 1.12 − 26.46 ± 1.87 18.75 ± 0.52 − 7.72 ± 
1.95 
PVA − 31.77 ± 5.23 − 25.19 ± 11.32 − 56.96 ± 12.24 38.08 ± 8.33 − 18.88 ± 
6.39 
EUD − 4.10 ± 2.09 − 5.55 ± 0.60 − 9.64 ± 1.84 7.73 ± 0.31 − 1.91 ± 
1.97 
HPMC 
Dimer systems 
− 20.35 ± 0.92 − 22.42 ± 0.79 − 42.77 ± 1.04 20.04 ± 0.43 − 22.73 ± 
0.82 
EUD-PVA − 13.83 ± 0.34 0.00 ± 0.00 − 13.83 ± 0.34 4.33 ± 0.10 − 9.50 ± 
0.36 
EUD-PVP − 10.78 ± 0.73 − 5.08 ± 0.43 − 15.87 ± 0.56 9.19 ± 0.33 − 6.67 ± 
0.64 
HPMC-PVA − 39.84 ± 0.74 − 12.88 ± 0.85 − 42.72 ± 1.00 17.50 ± 0.62 − 25.22 ± 
0.79 
HPMC-PVP − 15.15 ± 1.37 − 24.91 ± 0.71 − 40.06 ± 1.19 24.46 ± 0.44 − 15.60 ± 
1.13 
HPMC-EUD − 13.17 ± 0.81 − 27.93 ± 0.78 − 41.10 ± 0.85 27.00 ± 0.40 − 14.10 ± 
0.84 
PVA-PVP − 26.09 ± 1.23 − 12.77 ± 1.11 − 28.86 ± 1.53 16.09 ± 0.56 − 12.77 ± 
0.60 
trend was also observed in both the HPMC and PVP 
complexes. This confirms that molecular docking 
demonstrates only the Bgeometric fit^ of two molecules 
and free energy binding calculations are still required when 
estimating molecular interactions [38]. As observed in the 
HPMC-PVA complex, significant improvements were noted 
in the thermodynamic energy upon inclusion of HPMC 
compared to the monopolymer PVA complex (Figs. 9 and 
10). This may have been a result of increased 
intermolecular surface area based on the interaction size of 
HPMC. The above characteristic features may also be used 
to explain the high binding energy of the Ethocel complex 
(Fig. 11). Increased molecular surface area due to the 
conformational flexibility of Ethocel may have allowed for 
greater 
hydrophobicinteractionswithdomperidone.Asageneraltren
d, greaterstability was seen in the polymersthatshowed 
enhanced interactive binding surfaces such as HPMC and 
Ethocel. 
Bioavailability studies 
The pharmacokinetic profile of domperidone in plasma 
after 
oraladministrationof10mg/kgdoseofDOMP,itsnanocrystals
, tablets having DOMP in nanoform and marketed product 
(Motilium®) via oral administration is shown in Fig. 12. 
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Numerous pharmacokinetic parameters, including area 
under the concentration-time curve, maximal plasma 
concentration, time to reach maximal plasma 
concentration and biological half-life, are shown in Table 3. 
Administration of domperidone at a dose of 10mg/kg 
showed an elimination phase from 10 to 12 h with an 
elimination half-life of 4.18 h with a clearance of 4051.3 
mL/h. The distribution phase was observed from 6 to 8 h 
with an observed volume of distribution of 24,470.8 mL. 
The absorption phase was noted from 0.3 to 4 h. The 
maximum plasma concentration was observed as 1.3 
μg/mL at 2 h; 4.9 μg h/mL was the area under the 
concentration-time curve from time 0 to 12 h. Marked 
changes in the pharmacokinetics of nanocrystals were 
observed. Administration as nanocrystals increased the 
plasma concentration of domperidone throughout the 
study; however, a noteworthy escalation has been noted at 
0.5 h (P < 0.01), 1– 2 h (P < 0.001) and 4 h (P < 0.05). The 
nanocrystal formulations resulted in a decreased 
elimination rate of domperidone as reflected from a 
significant increase in half-life of 13.34 h (P < 0.001). A 
significant increase in plasma concentration of 2.6 μg/mL (P 
< 0.01) with a significant decrease (P < 0.01) in time (1 h) to 
reach maximum plasma concentration was observed 
compared to domperidone-treated rats. The nanocrystals 
increased the plasma exposure of domperidone as a 
significant increase in the AUC from time 0 to 12 h was 
observed (13.3 μgh/mL,P < 0.001). 
Similarly,thenanodosageform also showed an 
enhancement in the pharmacokinetic parameters, i.e. half-
life (8.3 h, P < 0.001), maximal plasma concentration (2.4 
μg/mL, P < 0.01), time to reach maximal plasma 
concentration (1.0 h, P < 0.01) and AUC (11.3 μg h/mL, P < 
0.001) , as compared to domperidone treatment. For the 
marketed drug, a significant increase in the apparent half-
life (6.45 h, P < 0.05) and AUC (7.73 μg h/mL, P < 0.05) was 
observed compared to the domperidone-alone-treated 
animals. 
Stability studies 
The physical stability studies of DOMP nanosuspensions 
stored at 2–8, 25 and 40 °C for 90 days showed that 
nanosuspensions stored at 2–8 and 25 °C (Fig. 13a, b) were 
 
Fig. 9 The lowest energy conformation of the HPMC-PVA-DOMP complex (− 25.25 kcal/mol): a the molecular surface of HPMC-PVA encapsulating 
DOMP and b the hydrogen bond interaction between DOMP and HPMC 
Fig. 10 The PVA-DOMP com 
plex ( − 18.88 kcal/mol): a molec 
between  ular surface interaction 
and PVA and DOMP b graphical  
representation of the lack of hy 
drogen bonds between PVA and  
DOMP  
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stable compared to the samples stored at 40 °C (Fig. 13c). 
The nanosuspension stored at 2–8 °C exhibited adequate 
stability (Fig. 13a) with no marked changes in key 
nanosuspension characteristics. The nanosuspensions 
stored at 2–8 and 25 °C maintained their PDI values, and 
there was no significant difference (P > 0.05, paired t test, 
 
Fig. 11 The lowest energy conformation of the Ethocel-DOMP complex (− 27.26 kcal/mol) after molecular dynamic simulations: a molecular 
surface interaction between Ethocel and DOMP and b three stabilising hydrogen bonds of the Ethocel-DOMP complex 
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one-way ANOVA) in and shape of crystallised materials [40, 
41]. Moreover, the polymeric media and associated 
stabilising agent are also considered very important and are 
known to facilitate surface stabilisation and consequent 
control of particle size during the nucleation process [42]; 
0.5% Ethocel was found the most suitable single polymer to 
effectively control the growth of the DOMP nanocrystals, 
which remained stable for 90 days 
25 °C (b) and 40 °C (c) 
(Table 4). This study demonstrated that sufficient 
adsorption of the polymers occurred onto the surfaces of 
the produced DOMP nanocrystals which resulted into 
strong repulsion of the particles and subsequent colloidal 
stabilisation. The molecular modelling studies also 
substantiated the experimental 
Table 3 Summary of 
Sample Pharmacokinetic par ameters   
t1/2 (h) Tmax (h) Cmax (μg/mL) AUC0–t (μg h/mL) 
Raw DOMP 4.182 ± 0.43 2.0 ± 0.11 1.3 ± 0.26 4.91 ± 0.31 
DOMP nanocrystals 13.34 ± 0.32*** 1.0 ± 0.07** 2.6 ± 0.18** 13.3 ± 0.44*** 
Tablets (DOMP nanocrystals) 8.334 ± 0.71*** 1.0 ± 0.09** 2.4 ± 0.21** 11.3 ± 0.39*** 
DOMP marketed formulation 6.451 ± 0.52* 2.0 ± 0.16 1.6 ± 0.31 7.73 ± 0.37* 
pharmacokinetic parameters for domperidone 
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n = 6, ± SD 
*P < 0.05; **P < 0.01; ***P < 0.001 
Table 4 Stability study of DOMP optimised nanocrystals as a function of time 
DOMP-polymer complexes 
Average particle sizes of DOMP nanocrystals with ± SD    
Day 0 Day 15 Day 30 Day 45 Day 60 Day 75 Day 90 
Ethocel-DOMP 130.0 ± 2.5 135 ± 3.0 140 ± 4.0 143 ± 3.5 144 ± 4.5 145 ± 3.8 147 ± 3.5 
Pluronic-DOMP 1200 ± 4.5 1280 ± 5.0 1385 ± 3.5 1450 ± 4.5 1600 ± 5.5 1730 ± 6.5 1850 ± 
6.0 
PVP-DOMP 950.0 ± 5.0 980 ± 5.5 1070 ± 6.0 1200 ± 4.5 1280 ± 4.0 1390 ± 7.0 1470 ± 
7.5 
PVA-DOMP 400.0 ± 4.5 440 ± 3.0 455 ± 2.7 470 ± 3.2 490 ± 2.4 520 ± 3.5 545 ± 2.8 
EUD-DOMP 1175 ± 7.0 1220 ± 3.7 1260 ± 3.5 1325 ± 3.7 1410 ± 2.5 1500 ± 2.0 1610 ± 
3.0 
HPMC-DOMP 300 ± 4.0 325.0 ± 2.0 338 ± 2.7 350 ± 2.0 370 ± 3.0 385 ± 3.5 392 ± 2.5 
EUD-PVA-DOMP 775 ± 6.0 800 ± 5.4 860 ± 5.5 930 ± 4.0 1020 ± 6.4 1100 ± 5.6 1170 ± 
6.0 
EUD-PVP-DOMP 985 ± 5.7 1015 ± 6.5 1090 ± 5.5 1210 ± 7.0 1300 ± 6.5 1410 ± 7.5 1515 ± 
5.8 
HPMC-PVA-DOMP 200 ± 3.5 210 ± 2.5 217 ± 2.0 230 ± 2.4 240 ± 3.0 245 ± 2.7 250 ± 2.5 
HPMC-PVP-DOMP 570.0 ± 5.0 600 ± 2.8 645 ± 3.5 680 ± 3.0 730 ± 3.7 790 ± 3.0 830 ± 3.2 
HPMC-EUD-DOMP 550 ± 5.5 575 ± 4.5 615 ± 5.0 650 ± 4.0 690 ± 4.5 710 ± 5.5 750 ± 6.0 
PVA-PVP-DOMP 650 ± 5.2 695 ± 5.5 730 ± 6.0 780 ± 6.5 830 ± 5.0 900 ± 4.5 945 ± 6.5 
results and suggested that Ethocel gave higher binding free 
energy (− 27.26 ± 0.24 kcal/mol) compared to other 
complexeswhich in turnprovidedhigherlevelsofsurface 
polymer adsorption and more effective stabilisation. In 
addition, DOMPnanocrystals producedby1% 
HPMCwerealsoshown to be stable compared to other 
single polymers. These binding free energies resulted for 
DOMP nanocrystals and HPMC (− 22.73 ± 0.82 kcal/mol) 
also suggest that HPMC could be effectively adsorbed onto 
the surface of DOMP nanocrystals with subsequent 
controlled particle growth. In the case of polymer 
combinations, the combination of HPMC-PVA was found 
the most suitable combination to retard the particle 
growth, because of its higher binding free energy (− 25.22 
± 0.79 kcal/mol) compared to other counterparts. 
Dissolution studies 
Figure 14 clearly shows that dissolution of DOMP has been 
increased enormously with the conversion of pure/raw 
DOMP to nanocrystals prepared by the antisolvent 
precipitation method. The difference in dissolution profiles 
of the produced DOMP nanocrystals formed in acidic and 
basic media is attributed to its physicochemical attributes. 
DOMP is basic in nature; therefore, it dissolves efficiently in 
acidic media [23]. The dissolution study of DOMP 
conducted in a buffer ( pH 6.8) medium resulted in 
approximately 80 and 20% release of the drug within the 
first 10 min, from nanocrystals and raw DOMP 
formulations, respectively. In addition, the dissolution 
studies conducted at acidic pH (0.1 M HCl) also resulted in 
enhanced dissolution rate for DOMP nanocrystals (38%) 
compared to the raw DOMP. Dissolution has been reported 
as being the rate-limiting step for BCS II class drug 
compounds, because they have high permeability but low 
dissolution rate [43]. Owing to increased dissolution rate of 
DOMP nanocrystals, the bioavailability could also 
potentially be enhanced, which is substantiated by the oral 
bioavailability 
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Fig. 14   Comparative dissolution profile of unprocessed and DOMP 
nanoparticles at acidic pH: 0.1 M HCl (a) and phosphate buffer pH: 6.8 
(b) 
studies in rates. Furthermore, nanocrystals have increased 
surface area and improved adhesiveness to the cell 
membrane which subsequently leads to high bioavailability 
[44]. The dissolution studies confirmed that the produced 
DOMP nanocrystals maintained their surface area and 
particle size. 
Conclusion 
This study concluded that polymers play an important role 
in the production of stable nanocrystals using the 
antisolvent precipitation method. This study provided 
molecular insight into the interactions between polymers 
and drugs at nanocrystal surfaces, the knowledge of which 
is not easily accessible through experiments. Ethocel was 
found the most effective polymer to control the particle 
size of DOMP nanocrystals (130.0 ± 2.5). Furthermore, the 
1% (w/v) HPMC-PVA combination also showed strong 
binding potential with DOMP nanocrystals demonstrating 
particle size 200.0 ± 3.5. The molecular modelling studies 
provided molecular level insight into polymer-drug 
interactions underpinning the mode of binding of polymers 
with DOMP at the surfaces of nanocrystals. This has 
provided an opportunity for the formulation scientist to 
rationally select the suitable polymers, most likely to 
achieve desirable particle size control for nanocrystals and 
deliver stable formulations which deliver optimal in vivo 
performance. 
DOMP nanocrystals showed enhanced dissolution rate 
at both acidic and basic pH conditions compared to the 
unprocessed form of DOMP. The dissolution enhancement 
for this BCS II class drug compound can potentially provide 
the opportunities to develop a more cost-effective dosage 
form having the same therapeutic performance but at 
much lower dose compared to the existing marketed drug 
product. 
Pharmacokinetic studies in rats have shown that the 
improved dissolution performance leads to markedly 
improved rate and extent of drug absorption in vivo. Future 
studies will be focussed on transforming the prototype 
formulations tested in this project into drug products 
suitable for clinical testing and commercialisation. 
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